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ABSTRACT

This dissertation presents work on the design and synthesis of a new membrane
chromatography material, the description of its protein binding behavior using a
thermodynamic adsorption isotherm model, and the application of the new membrane
material in biologics downstream recovery and purification processes. As protein titers
continue to increase dramatically in upstream biomanufacturing, innovations in downstream
purification are not keeping pace, resulting in manufacturing capacity constraints and high
production costs. Chromatography is the key unit operation used in several steps of the
downstream purification platform. Traditional resin bead chromatography, while effective
and reliable for isolation and purification of proteins, limits the process productivity and
affects product quality. In the case of ion-exchange chromatography steps, traditional
materials have a limited operating window, which requires the implementation of buffer
exchange steps between chromatography steps to condition the feed for optimal performance
in each step. Innovations in purification technologies that can dramatically increase the
productivity of existing facilities and simultaneously lower the manufacturing cost are
needed. In this dissertation, a new multimodal membrane chromatography material is
introduced that could greatly improve the process productivity and product quality.

Chapter 2 describes my work to develop the first cation-exchange multimodal membrane
(MMM) adsorber in a two-step synthesis. Surface-initiated atom transfer radical
polymerization was used to graft polymer chains containing epoxy side groups from the
surface of a commercial macroporous regenerated cellulose membrane. Then, the multimodal
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functional groups were introduced through an epoxide ring opening reaction by 4mercaptobenzoic acid. Permeability and protein (IgG) binding capacity measurements
showed that polymerization time can be used to achieve high binding capacity (up to 180 mg
IgG/mL) while maintaining adequate permeability of the membrane. Kinetic studies with a
model cellulose nanolayer suggest that the degree of polymer grafting directly affects the
static binding capacity of the multimodal membrane. Measured equilibrium IgG binding
capacities using protein solutions at different pH values and ionic strength values
demonstrated that both Coulombic and hydrophobic interactions occur between the protein
and the membrane. Characteristic of multimodal adsorbers, the multimodal membranes
maintained significant binding capacities in excess of 90 mg IgG/mL at ionic strength values
that are typical for elution buffers used in multi-stage bioseparation processes. For sodium
citrate, a conventional salt used in elution buffers of Protein A columns, increasing ionic
strength had only a minor effect on the IgG binding capacity. These results indicate that the
newly developed multimodal membrane has great potential to compete with more traditional
cation-exchange materials following the Protein A purification step in the downstream
processing of antibody products. In addition to work with macroporous membrane supports,
a new method was developed to coat cellulose nanolayer on silicon wafer to mimic the
morphology of cellulose membrane surface. A kinetic study with the model cellulose
nanolayer showed that the polymer thickness is proportional to the static binding capacity of
the multimodal membrane. This model substrate could be useful for future membrane design
efforts.

Chapter 3 describes my work to evaluate the effects of different salt types (kosmotropic,
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neutral, chaotropic salts) and ionic strength on IgG binding. Dynamic binding capacity
measurements were performed over a range of flow rates. A thermodynamic model was used
to provide insights on the nature of protein-MMM interactions and to predict binding
capacities under non-test conditions, which is important for limiting the number of
experiments needed for process development. It was determined that the rate limiting step of
IgG adsorption on the MMM is the reaction rate of IgG binding with the multimodal ligands,
rather than the mass transport of protein molecules. Thus, while high load productivities were
achieved, improvements in membrane design leading to faster adsorption kinetics would
enable still higher productivities. The results of this part of the study indicate that multimodal
membrane bind-and-elute chromatography can be a highly productive and scalable process.
The ability to work at high salt concentrations may reduce the number of steps in the protein
purification train, improving product quality, enhancing manufacturing capacity in existing
facilities, and reducing the cost of downstream purification.

Chapter 4 describes my work to purify monoclonal antibodies from Chinese hamster ovary
(CHO) cell culture supernatant using the newly designed multimodal membranes. When used
after a size exclusion desalting step, the MMM column was effective for recovery of human
IgG1 from CHO cell culture supernatant, and neutral pH elution yielded a product pool with
purity (>98%) and HCP level (n.d.) equivalent to what could be achieved by Protein A
chromatography. Dynamic capacities at 1 CV/min were higher for the MMM column than
the commercial Protein A resin column, which is important for reducing the number of
cycles needed for purification of a batch and thereby increasing process throughput. Whereas
it is unlikely that Protein A chromatography will be replaced anytime soon for mAb capture
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step purification, this part of my work showed that MMM chromatography following a
simple desalting step appears to be an excellent option for capture step purification of
proteins when Protein A cannot be used, e.g., for pH sensitive mAbs or biologics lacking the
Fc binding domain.

Overall, this dissertation demonstrates the potential of multimodal cation exchange
membranes for the effective and high-productivity purification of proteins from cell culture
supernatant, either in bind-and-elute mode following a desalting step, or in polishing step
mode following a Protein A capture step. Its ability to operate over a wide range of
conditions may reduce the number of steps needed to purify proteins, which would increase
the overall process productivity and also improve the product quality.
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CHAPTER 1

INTRODUCTION

1.1 Rapid development of the biopharmaceutical market
Biopharmaceuticals, i.e., drugs produced using biotechnology, are high in demand, and it is
estimated that 48% of the top 100 drugs will be biologics by the end of 2016[1]. By the end
of 2014, biopharmaceuticals generated global revenues of $163 billion, making up about 20
percent of the total pharmaceutical market. The biopharmaceutical market is expected to
grow to an estimated value of $278 by 2020[2]. It is by far the fastest growing part of the
pharmaceutical industry.

Biopharmaceuticals include such compounds as proteins (including peptides, antibodies),
nucleic acids (such as DNA, RNA, oligonucleotides) and viruses. Biopharmaceuticals
functionally and structurally imitate compounds found in life forms and can be used for
therapeutic or in vivo diagnostic purposes. Compared with traditional chemical
pharmaceuticals, biopharmaceuticals generally are more effective and safer because of their
specificity[3]. The first biopharmaceutical substance approved for therapeutic use was human
insulin in 1982. In the years since that first approval, advances in the production of
biopharmaceuticals have dramatically changed the approach to treatment of many diseases
such as diabetes, cancers, malignant disorders, etc.

Therapeutic proteins have become the most important sector of the biopharmaceutical
industry. With the advent of recombinant DNA-technology, proteins can be generated in
1

specific host cells under defined conditions. The fastest growing class of therapeutic protein
is antibodies. In the period from 2006 to 2009, half of the genuinely new biopharmaceuticals
that came to market were antibodies[4]. As of November 2014, 47 monoclonal antibody
products have been approved in the US or Europe for the treatment of variety of diseases. By
2020, the world-wide sales of monoclonal antibody products will be nearly $125 billion [5].

1.2 Biopharmaceutical manufacturing
Biopharmaceutical manufacturing is complex and variable by product. Generally, it is
composed of two steps: upstream processing- the process including cell isolation and
cultivation, cell banking, cell expansion and live cell collection (final harvest), fermentation;
and downstream processing- the chemical and physical separation operations used to isolate
and purify the target product from a complex cell culture solution, and formulate it for use.

The increasing demand for biologics together with the introduction of biosimilars to the
market is pressuring biopharmaceutical companies to increase manufacturing process
productivity and decrease costs to remain competitive. In the past two decades, upstream
processing has achieved significant progress. By developing recombinant technologies as
well as media and process control strategies, process efficiency, achievable cell densities and
product titers have increased markedly in the cell culture process. Nowadays, it is common to
have antibody titers of 3-5 g/L. Some have reported antibody titers above 10 g/L[6,7], even
as high as 25 g/L [8,9]. Therefore, by overcoming the biological limits through changes in
the cell line or media optimization, upstream capacity can be increased greatly without
raising the costs. However, these successes generate challenges for downstream purification.
2

Cell culture solutions that enter downstream processes with high product titer result in
increased processing times, materials consumption and costs. Additional challenges
presented by high product titers include the types and concentrations of impurities that must
be removed in downstream operations. Downstream processing has become the bottleneck
that limits the manufacturing capacities of most facilities and accounts for a majority of
product production cost[10].Thus, it is necessary to develop new approaches for improving
the productivity and lower the cost of downstream purification. It is likely that achieving
these goals will involve both the optimization of current strategies and development of
innovative new technologies and processing methods described later in this chapter.

1.3 Chromatography operations
The train of downstream processing operations comprises three sectors- clarification,
purification and polishing. The primary goal of cell disruption is to harvest the target product
in solution while removing suspended materials like cells and cell debris by centrifugation or
filtration. The primary goal for purification and polishing operations is to separate the target
product from impurities while keeping the product concentrated and stabilized.
Chromatography is the primary unit operation used for purification and polishing steps and,
thus, plays a key role in downstream processing. The following paragraphs will briefly
introduce the chromatography modes that are used commonly in the downstream operations.

Affinity chromatography is a powerful method for selectively recovering a specific molecule
or a group of molecules from a complex mixture. In the case of protein purification, affinity
3

chromatography separates proteins from mixture components on the basis of a reversible
biospecific interaction between the protein and a specific ligand on a chromatography matrix.
Because of the high selectivity for the protein(s) of interest, the product protein is collected in
a purified and concentrated form. For a successful affinity separation, it is important to have
sufficient affinity between ligand and target molecule. In general, an apparent equilibrium
binding constant in the range of 106-108 M-1 can be used for affinity-based purification[11].
Some typical biological interactions frequently used in affinity chromatography are enzyme
and substrate, antibody and antigen, lectin and polysaccharide, nucleic acid and
complementary base sequence/histones, hormone and receptor, glutathione and glutathioneS-transferase, metal ions and oligo(His) fusion proteins, among others.

In theory, a selective ligand can be developed to purify any target product. However, the
availability or effort required to design new ligands and the efforts to understand the coupling
chemistry of the ligands to the chromatography matrix may be too lengthy and costly.
Therefore, the use of non-affinity-based purification techniques such as ion exchange and
hydrophobic interaction chromatography may be a better choice.

In the 1960s, ion-exchange chromatography (IEX) was introduced to the applications for
biomolecule separations [12,13]. Today, it has become the most widely used technique for
purification of biomolecules such as proteins, peptides, nucleic acids, etc. IEX separates
molecules based on the attraction of oppositely charged groups. Since all molecules with
ionizable groups can be titrated, their net surface charge is highly pH dependent. Take
proteins as an example, their net surface charge will change gradually as the pH of the
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environment changes. Each protein has its own specific isoelectric point (pI) value, at which
pH the protein has no net charge. At pH values above its pI, the protein has a net negative
charge and binds to anion-exchange media. At pH values below its pI, the protein has a net
positive charge and binds to cation-exchange media. Ion exchangers bind target molecules
primarily through Coulombic interactions. Strong ion exchangers are charged in aqueous
media over a wide range of pH; whereas, weak ion exchangers usually have a narrow pH
operation window. To elute bound proteins from ion exchangers, it is typical to increase the
ionic strength of the buffer to disrupt Coulombic interactions via charge screening effects, or
to change the pH to alter the net charge of the protein and/or ion exchanger to create
repulsive charge interactions. The primary advantage of IEX is that it can separate molecules
that have only minor differences in their charge properties. However, when used for
chromatographic bioseparations, optimizing the sample loading conditions (such as pH, ionic
strength, ion composition) is the key to achieving the most effective separation and utilizing
the full binding capacity of the ion exchange medium. Therefore, additional unit operations
like diafiltration for buffer exchange and desalting or sample dilution often must be used
prior to each IEX step to optimize the loading conditions.

Hydrophobic interaction chromatography (HIC) used for protein purifications was first
reported independently by Yon and Shaltiel in 1972 [14]. In both of the cases, hydrophobic
solid supports were synthesized by coupling aminoalkane derivatives to agarose. As
Israelachvili puts it [15], hydrophobic interactions constitute ‘the unusually strong attraction
between non-polar molecules and surfaces in water’. HIC separates proteins based on
differences in their surface hydrophobicity by utilizing a reversible interaction between these
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proteins and the hydrophobic surface of a HIC medium. In addition, salting-out and salting-in
effects are important considerations in HIC operation. Porath and coworkers [16] first
showed the enhancement of hydrophobic interaction by the presence of high salt
concentration. The effect of salt type on the adsorption and elution of proteins follows the
Hofmeister series (see Figure 1.1). On the left side of the series, ‘kosmotropic’ salts enhance
hydrophobic interactions and promote the binding to HIC media. On the other side of the
series, ‘chaotropic’ salts decrease hydrophobic interactions and interrupt the binding to HIC
media. Selective elution of bound proteins can be achieved either by gradually lowering the
kosmotropic salt(s) concentration or increasing the chaotropic salt(s) concentration. Proteins
will be eluted in the order of hydrophobicity.

Figure1.1 Hofmerister series

1.4 Media for chromatography columns
Ideal features for a chromatography medium used for bioseparations are high selectivity,
high binding capacity, efficient mass transfer, incompressibility, chemical stability, nontoxicity of leachables, high number of cycles, and cost effectiveness [17]. Chromatography
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media used for process scale bioseparations generally can be classified into three categories:
resin beads, monoliths, and membranes.

Resin beads are the most widely used chromatography media in the biopharmaceutical
industry. In 1956, Peterson and Sober [18] first reported the preparation of cellulose beads
with ion-exchange functionality used as a chromatography medium for protein adsorption (i.e.
bovine plasma albumin, equine carbon monoxide hemoglobin). Since then, most work has
been done with dextran- and agarose-based chromatography beads, e.g., Sephadex and
Sepharose. They generally have more efficient mass transfer properties than cellulose beads,
which leads to improved protein separation[19]. Other frequently used resin support
materials for biochromatography are polymers such as polyacrylamide and polystyrene.
Although they are more hydrophobic, they generally have a better resistance to aggressive
chemical conditions like those used for cleaning steps between cycles. While effective and
reliable, resin-based chromatography has several limitations that have been summarized by
many authors (e.g., [20,21]). Firstly, the resin-bead column causes relatively high pressure
drop with operation due to media deformation/compression and pore blocking by
accumulation of colloidal debris from the feed stream. For this reason, bed heights generally
are kept below about 50 cm, thus requiring large diameter (1-2 m) columns to provide
sufficient media volume. Secondly, diffusion is the primary transport mechanism of
biomolecules to binding sites inside resin-bead columns. Since the majority of binding sites
(>90%) are located inside the pores of resin beads, biomolecules have to diffuse into the
small channels within the beads to adsorb on binding sites. It is a slow transport mechanism,
and thus a long residence time is required to utilize the bed efficiently. Furthermore, attempts
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to decrease residence time lead to lower dynamic binding capacities. For this reason, resin
columns generally are designed to be oversized to provide sufficient binding capacity at
realistic residence times[22]. Thirdly, the scale up of resin bead chromatography columns
requires adjustment of column aspect ratio to optimize binding capacity versus desired
volumetric throughput. Because scale up is non-linear, much time and effort is expended by
process development engineers for process scale up.

Monoliths are a class of stationary phase in which the support is cast into a chromatography
column as a continuous block interlaced with channels [23]. The large channel diameter
results in monoliths with excellent mass transfer properties (convective flow of proteins to
binding sites) and a low pressure drop across the column [24]. Hjerthen [25] and Tennikova
[26] developed the first monoliths. Nowadays, monolithic columns are used widely for
analytical bioseparations. Limitations on scale up, uniform flow distribution, and achievable
binding capacities have prevented monoliths from being implemented for process scale
bioseparations[27,28].

Membranes were introduced as chromatography supports to overcome the limitations with
resin-bead columns[29]. Typically, macroporous membranes with nominal effective pore
diameters from 0.2 to 5 μm are used to facilitate the transport of biomolecules to binding
sites. Like for monoliths, convection is the predominant transport mechanism within
membrane columns, which results in short residence times and, therefore, high-productivity
separations. Furthermore, dynamic capacities are insensitive to flow rate, as long as the
residence time is longer than the characteristic time for protein adsorption[30]. The pressure
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drop across the membrane column can be significantly lower than with resin-bead
columns[27]. In addition, membrane chromatography columns are easy to scale-up. Despite
the many advantages of using a macroporous membrane support, the use of membrane
adsorbers for bioseparations has been limited historically because of their low surface area to
bed volume ratio, which limits binding capacity. Attempts to increase the surface area
generally compromise other membrane properties such as mechanical strength and
permeability. One strategy to increase membrane binding capacity is to coat the pores of a
support membrane with functional polymers. Coating methods that apply a preformed
polymer to the surface either physically or covalently (a.k.a. grafting to approaches) can be
used. For example, the Belfort group and the Ulbricht group have done extensive work on
using photografting to grow polymer layers on membranes. However, it is difficult to control
the coating thickness and therefore the effective pore size [31]. The Husson group has
pioneered[32] and patented[33] the use of surface-initiated atom radical transfer
polymerization to controllably graft polymer chains from membrane pore surfaces. In
numerous papers (e.g., [30,34,35]), the group has shown that this is an effective method to
increase binding capacity by creating three-dimensional adsorptive polymer scaffolds on the
membrane pore surfaces while maintaining good permeability and stability. As described in
this dissertation, I used this polymer grafting approach to prepare a new class of membrane
materials with high binding capacity over a range of operating conditions.

1.5 Disposable technologies in biopharmaceutical manufacturing
In biopharmaceutical manufacturing, single-use and “disposable” technologies are being
adopted at a rapid pace. While these terms often are used interchangeably, the industry
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generally distinguishes disposable technologies as ones that are used to process a single batch
versus single-use technologies as ones intended for a one-time use. The guidelines of cGMP
are used to tightly control the production of all drugs to reduce or prevent contamination of
the product stream with bacteria, viruses and other potentially harmful adventitious agents.
According to cGMP, cleaning is the key operation between runs of vessels and other
equipment that comes into contact with the product. This is a laborious and time-consuming
requirement that means the manufacturing process must be taken off line, and the cleaning
procedure must be extensively validated and documented. Therefore, single use and
disposable technologies have the advantages of avoiding cleaning and validation
requirements and simultaneously reducing the risk of contamination. Single use and
disposable technologies save time getting a facility up and running between campaigns, and
also reduce capital costs on stainless steel equipment. Compared to a traditional hard-piped
facility, it has been reported that a new single use system for a production facility can reduce
capital cost by up to 40% [36].

In the early 1970’s, Knazek and his team [37] developed the first hollow fiber bioreactor in
which mammalian cells could be cultured at high cell densities. Hollow fiber membranes
were used in a disposable cartridge for a continuous culture processing in perfusion mode.
This formed the basis for the popular in vitro diagnostic and therapeutic mg-scale production
of antibodies in the 1980s. In the 1990s, polystyrene Cell Factories developed by Nunc and
Bioferon [38] replaced the roller bottles used for cell expansion. Disposables are now widely
used for inoculum expansion processes, and they also can be used as the production
bioreactor when smaller cell culture volumes are sufficient. The introduction of the WAVE
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bioreactor catalyzed the rapid further development of single use technology, as it was the
first to be applied for large scale production. Over the past decade, the market for single use
systems has been expanding steadily. In 2009, a 35% growth rate was reached, however,
largely from products for upstream processing [39].

The increasing use of single use technologies in upstream processing drives the development
of single use and disposable products for downstream processing. The first single use
systems were in-process microfilters for bioburden control between process steps[40]. In the
late 1990s, membrane chromatography was first introduced as a process step and constituted
the first single-use technology that was intended to replace a conventional option (preparative
chromatography on columns)[40-42]. Today, prepacked chromatography columns are the
fastest growing segment of disposables in downstream processing[43]. Although membrane
chromatography has the lowest take-up of all disposable devices, currently featured in 19%
of commercial processes [44], it is also the most recent addition to the family of disposable
concepts and has the strongest market growth.

1.6 Process optimization and compression
With the rapidly increasing demand for biologics and the introduction of biosimilars into the
market, biopharmaceutical manufacturers are seeking innovations in purification
technologies and processes that can dramatically increase the production capacity of existing
facilities and simultaneously lower the manufacturing cost to be competitive. The current
expensive production processes need to be improved while effectively utilizing existing
facilities to limit financial risk in building and validating new facilities. Innovations in
11

biomanufacturing technology are helping to reduce the cost of production, improve the
quality of products and lessen limitations on operation conditions. While it seems necessary
for biomanufacturers to invest in process development and implementation of new unit
operations, the reality is that innovations that can operate within the current manufacturing
framework are the ones most likely to be adopted. For this reason process optimization and
compression are hot topics, particularly for downstream processing.

Improvements in upstream processing largely result from improving cell lines and optimizing
processing conditions. Process efficiency, achievable cell densities and product titers can be
increased in cell culture processes by developing recombinant technologies and improving
media and process control strategies. Upstream improvements mostly depend on pushing
biological limits on product titer, and, therefore, these can be implemented without
significant investment in process scale-up or new facilities. In the past two decades, upstream
capacity has been greatly increased by increasing product titer, not processed volumes.
However, these high concentration feeds enter downstream processing facilities that were
designed for much lower masses of antibody. The result is an increase of process time,
material consumption and costs of purification. With high titers, downstream processing may
account for 60-90% of total cost for biologics production [45,46]. More troubling, a survey
of over 400 executives from the biopharmaceutical industry [47] found that 78.6% expect to
see near-term capacity constraints. Among the factors expected to create production capacity
constraints are physical capacity of downstream purification equipment (29.6%), lack of
financing for production expansion (22.4%), and costs associated with downstream
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purification (18.2%). To find a solution for these problems, new downstream purification
strategies and technologies are needed.

Figure 1.2 illustrates the downstream process platform for mAb production. After cell
harvesting by centrifugation or filtration, chromatography is the primary technique used to
isolate antibodies from fermentation broth and purify them prior to formulation. Protein A
resin chromatography is the capture step operation for antibody isolation due to the high
specificity by Protein A for binding to the Fc region of mAbs. Protein A chromatography is
expensive due to high materials cost ($12,000-15,000 per liter). In addition, leached Protein
A is a toxic process-related impurity that must be removed by subsequent polishing steps.
Many suppliers offer alternatives to Protein A resins, and these alternative resins may offer
better alkali resistance, higher binding capacity and improved reusability. However, a survey
conducted by BioPlan Associates indicates about 30% of companies had experience testing
alternatives to Protein A chromatography, and only 7% had implemented them [48]. Protein
A alternatives are still in their infancy, and may be expected to find more widespread use
with the emergence of new biologics lacking the Fc binding domain.

Following Protein A chromatography, IEX chromatography (IEC) typically is used in one or
two steps to remove residual impurities such as remaining host cell proteins (HCP) and
DNA, product aggregates, endotoxins and virus particles associated with the cell line [49].
HIC is complementary to IEC and Protein A, and can be used for further polishing. In flowthrough mode, HIC removes mostly aggregates; in bind-and-elute mode, it can remove other
impurities [49]. Buffer exchange steps are needed between chromatography steps to
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condition the feed for optimal performance of each step. The process also includes two
orthogonal steps for viral clearance: low pH viral inactivation after Protein A
chromatography and viral filtration after polishing chromatography. The final process step is
ultrafiltration/diafiltration (UF/DF) to formulate and concentrate the product.

Figure 1.2 Monoclonal antibody downstream process. Reproduced with permission from
A.A. Shukla, J. Thömmes, Recent advances in large-scale production of monoclonal
antibodies and related products. , Trends Biotechnol., 28 (2010) 253-261; Copyright (2010)
Elsevier.
The platform purification process illustrated in Figure 1.2 does not have a set of number of
chromatography steps. The number of steps to be included will depend on the purity
requirements and the complexity of the starting materials. Increasing the number of
purification steps will always decrease the overall yield. Further, more steps means longer
purification time. This can be detrimental to protein stability and activity. To reduce the
number of steps while meeting the purity requirements, the biopharmaceutical industry is
exploring new chromatography media. Multimodal chromatography media offering new
selectivities are of interest because they can provide two or more orthogonal interactions
within one chromatography step. In addition, the wide operating range offered by these
14

media may eliminate the need for buffer exchange steps between operations. Thus, a
multimodal purification step enables reduction of the number purification steps [50].
Multimodal membranes would offer an additional benefit of increasing purification
productivity by decreasing the residence time.

1.7 Bioseparations using multimodal media
Multimodal chromatography (MMC) offers an alternative to a series of unimodal
chromatography steps. For example, Coulombic and hydrophobic interactions as occur in
IEC and HIC can occur at the same time, which frequently may increase the selectivity and
specificity of the unit operation relative to IEC and HIC alone. The concept of MMC was
first introduced as early as in the 1950s with the use of mineral hydroxyapatite [50]. However,
only within the last decade has MMC started to receive strong interest from both academia
and industry. MMC media typically are designed for specific purposes, including operation
under high-salt concentrations, pH-tunable hydrophobicity, and capture of target biologics
from feed solutions [51-53].

For bioseparation applications, most multimodal ligands are designed based on hydrophobic
and Coulombic interactions, since HIC and IEC are the most commonly used
chromatographic purification steps. A typical hydrophobic-Coulombic multimodal ligand
should at least include one hydrophobic moiety and one ionic moiety. Ligands that serve as
the hydrophobic moiety oftentimes include butyl, phenyl and hexyl groups. Ionic moieties
include both strong (sulfonic and quaternary amine groups) and weak (carboxyl and amine
groups) ligands. The degree of hydrophobicity should be carefully selected to achieve a
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reasonable balance between hydrophic binding ability and sufficient hydrophilicity of the
adsorber material to be wetted by the feed solutions. MMC media with strong ion-exchange
groups maintain their charges over a wide range of pH and act permanently like multimodal
ligands. MMC media with weak ion-exchange groups can be used in hydrophobic charge
induction chromatography (HCIC mode). For example, protein can be adsorbed only through
hydrophobic interactions and then be eluted by pH-induced charge repulsion.

One of the most frequently used multimodal ligand types for protein separation is
hydrocarbyl amine. Hexylamine- and phenylpropylamine-Hypercel [54] are two commercial
resin products based on this ligand type. The amine groups serve as the charge group, while
hydrocarbyl groups provide opportunities for hydrophobic interaction with target molecules.
Another unique class of multimodal ligands are heterocyclic compounds, which have the
merits of their specific aromaticity/hydrophobicity and dissociation properties. MEP
Hypercel is a commercial product based on this ligand type [55,56]. At physiological
conditions, MEP ligands have no charge and adsorb protein molecules only through
hydrophobic interactions. To release proteins from the ligands, the mobile phase has to be
changed to acidic condition (pH<4), at which MEPs are positively charged and repel the
positively charged proteins.

It has been reported that hydrogen bonding groups in the proximity of the ionic groups in
multimodal ligands could facilitate protein binding at high salt concentrations [51,52].
CaptoTM MMC and CaptoTM Adhere are two commercial resin products that utilize this type
of ligand. Generally, with the presence of hydrogen bonding, hydrophobic and Coulombic
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interactions, the MMC media can achieve high binding capacities over a wide range of salt
concentrations. As for the elution step, the adsorbed protein can be released by both
increasing salt concentrations and pH adjustment. The Cramer group from Resselaer
Polytechnic Institute also has done excessive studies on using displacers to elute proteins
from chromatographic columns (e.g. [57-59]).

Multimodal media offer a new alternative to Protein A resins for efficient and selective
capture of proteins from cell culture solutions. Lund et al. [60] developed a new multimodal
ligand that can adsorb IgG with binding capacity up to 48 mg/mL. MEP HypercelTM is also
reported to be selective for antibody binding [61]. Furthermore, elution of proteins from
MMC columns can be done under gentler conditions that Protein A chromatography, which
requires low pH. Touille and coworkers [62] have reported that MMC can use less acidic pH
for elution while removing aggregates and contaminates like HCPs. Missing from the
conversation prior to my work has been the development of high-capacity, high productivity
multimodal cation-exchange membranes for capture step protein purification.

1.8 Outline of the dissertation
The goal of my doctorate work was to develop a new class of multimodal membrane
materials as chromatographic adsorbers for biopharmaceutical downstream purification.
My dissertation is organized into three parts: 1) preparation of multimodal membranes, 2)
evaluation of the membrane performance with synthetic solutions of Immunoglobulin G (IgG)
as model protein, 3) development of an improved purification strategy to capture monoclonal
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antibody from a real Chinese hamster ovary (CHO) cell culture supernatant by applying
MMM chromatography. These parts are described in Chapters 2-4.

Chapter 2 describes a graft polymerization strategy to prepare multimodal membranes, a new
class of high-productivity adsorptive materials for the purification of therapeutic proteins.
Surface-initiated atom transfer radical polymerization was used to graft poly(glycidyl
methacrylate) ‘tentacles’ from the pore surfaces of macroporous regenerated cellulose
membranes. Subsequently, 4-mercaptobenzoic acid was coupled to the membranes by an
epoxide ring-opening reaction. Spectroscopy measurements supported successful ligand
incorporation. Graft polymerization studies from cellulose-coated silicon substrates were
done in parallel to measure the thickness evolution of the polymer coating, which plays an
important role on protein binding capacities. Protein binding experiments with bovine
immunoglobulin G showed that the multimodal membranes have high equilibrium capacities,
up to 150 mg IgG/mL. The binding capacities were found to be pH-dependent, with
maximum binding at pH near the protein isoelectric point. Characteristic of multimodal
adsorbers, the membranes retain about 70% of their equilibrium binding capacity at moderate
ionic strength (300 mM) and about 40% at high ionic strength (1.6 M).

Chapter 3 describes research on the use of the newly developed multimodal membrane
(MMM) adsorber as a chromatographic stationary phase in bioseparation processes.
Compared with commercial cationic multimodal adsorbers, this MMM was found to have
superior static binding capacity (SBC = 180 mg IgG/ml), dynamic binding capacity (DBC10%
= 60 mg IgG/ml), and load productivity (>10 mg/ml/min). Furthermore, the incorporation of
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functional groups that provide orthogonal modes of interactions increased the range of ionic
strength for operation of the MMM relative to conventional ion-exchange and hydrophobic
interaction chromatography media. The effects of different salt types (kosmotropic, neutral,
chaotropic salts) and ionic strength on IgG binding were investigated. To further understand
the protein adsorption on the MMM, a thermodynamic model was employed to describe IgG
adsorption isotherms on the MMM by providing a unique set of physically meaningful
parameters for each salt type. The model was also a precise predictor of the adsorption
isotherms under non-test conditions. A breakthrough analysis was used to determine dynamic
binding capacities. The MMM maintained 70% DBC as ionic strength increased from 0 to
300 mM NaCl. Finally, a range of flow rates was used to study the effect of volumetric
throughput on DBC. Because DBC was insensitive to flow rate, process productivity
increased with flow rate nearly linearly up to high linear velocity (535 cm/h). A kinetic study
indicated that the rate limiting step of IgG binding on the MMM was the adsorption rate, not
the convective mass transport of protein molecules to binding sites.

Chapter 4 describes strategies to purify monoclonal antibodies from CHO cell culture
supernatant using the newly designed multimodal membranes. The MMMs were used for the
capture step purification of human IgG1 following a size-exclusion desalting column. The
MMM column attained higher dynamic binding capacity than a Protein A resin column at an
equivalent residence time of 1 min. The two step MMM chromatography process achieved
high selectivity for capturing hIgG1 from the CHO cell culture supernatant. Product purity
and HCP level in the elution pool were analyzed and compared to results from a commercial
Protein A column. The product purity was >98% and HCP levels were < 20 ppm for both
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purification methods. In addition, hIgG1 could be eluted from the MMM chromatography
column at neutral pH, which is important for limiting the formation of aggregates. Overall,
this chapter shows that MMMs are highly effective for capture step purification of proteins
and should be considered when Protein A cannot be used, e.g., for pH sensitive mAbs or nonmAb proteins.

Chapter 5 summarizes the conclusions of my doctoral research work and gives
recommendations for future study.

Publications from my doctoral research work at the time of dissertation submission include
the following:

Wang, J.; Sproul, R.T.; Anderson, L.S.; Husson, S.M. Development of multimodal
membrane adsorbers for antibody purification using atom transfer radical polymerization.
Polymer, 55, 1404-1411 (2014). (Associated with Chapter 2)

Wang, J.; Wilson, A.; Robinson, J.R.; Jenkins, E.W.; Husson, S.M. A new multimodal
membrane adsorber for monoclonal antibody purifications. J. Membr. Sci. 492, 137-146
(2015). (Associated with Chapter 3)

Wang, J.; Zhou, J.; Gowtham, Y.; Harcum, S.W.; Husson, S.M. Antibody purification from
CHO cell supernatant using new multimodal membranes. Biotechnol. Bioeng., under review.
(Associated with Chapter 4)
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Jenkins, E.W.; Wilson, A.B.; Wang, J.; Husson, S.M. Analysis of a time-integrated SUPG
framework for numerical simulation of adsorption models. Appl. Comput. Math., under
review.
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CHAPTER TWO

DEVELOPMENT OF MULTIMODAL MEMBRANE ADSORBERS FOR
ANTIBODY PURIFICATION USING ATOM TRANSFER RADICAL
POLYMERIZATION
[As published in Polymer, 55 (2014) 1404-1411, with minor modifications]

2.1 Introduction
Development of efficient separation processes for biotherapeutics has been highlighted as
one of the most pressing challenges facing the pharmaceutical and biotechnology industries
[1]. Protein therapeutics, and specifically monoclonal antibodies, are high in demand. It is
estimated that eight out of the top ten drugs will be biologics in 2016 [2]. Production costs
for these drugs have shifted from upstream cell culture to downstream recovery and
purification, bringing economic pressure to develop new separations technologies. Without
intervention to improve the downstream manufacturing capacity, there will be increasing
shortages of these products, especially for those used in high doses to treat chronic diseases.

In practice, downstream processing to purify biologics from crude cell culture media often
uses centrifugation and depth filtration for removal of intact cells and cell debris, followed by
one or more chromatography steps, followed by ultrafiltration/diafiltration for product
concentration and formulation [3]. The most commonly used chromatography techniques are
affinity, ion-exchange, and hydrophobic-interaction chromatography. Purification with these
techniques relies on a dominant or ‘single’ mode of interaction that limits their range of
operating conditions. An example is the limit imposed by ion-exchange media on feedstock
ionic strength.
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Alternatively, multimodal chromatography uses resins with ligands that target specific
combinations of protein-ligand interactions [4,5] that include Coulombic interactions,
hydrophobic interactions, and hydrogen bonding. Coulombic interactions may play a
significant role at low to moderate ionic strength, while hydrophobic interactions play a
significant role at high ionic strength. The additional flexibility in designing purification
strategies that employ multimodal materials makes them attractive candidates to face
emerging challenges in industry, such as the need for more selective chromatography media,
improved resolution, and tolerance of feedstock conditions [6,7].

However, the current resin-based multimodal chromatography platform commonly finds that
binding capacities decrease with increasing column throughput. This result can be explained
by the fact that shorter residence times within the column lead to a decrease in intraparticle
protein mass transport to binding sites. Using polymeric membranes in the downstream
chromatography steps is therefore appealing and potentially transformational because
dynamic protein binding capacities of these materials do not depend on throughput, and, thus,
volumetric productivity can be very high compared to more traditional chromatography
materials.

A number of graft modification strategies have been used to develop membranes for
bioseparation applications, and we have summarized many of the various approaches in
prior publications [8,9]. Of particular relevance to the current work are those approaches
that graft polymers with side-chain functional groups that serve as reactive sites to attach
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ligand groups for protein binding. Our group and others [8-18] have demonstrated that,
among the numerous approaches, surface-initiated atom transfer radical polymerization is an
attractive method to graft polymer chains from membranes pore surfaces in controllable ways.
Polymerization time can be used to control the effective average pore size of membranes and
ion-exchange capacities [8,10]. High protein binding capacities can be achieved by grafting
functional polymer chains from the pore surfaces of a variety of base membranes.

In this study, we used surface-initiated ATRP to graft poly(glycidyl methacrylate) from
macroporous regenerated cellulose support membranes. The resulting membrane provides an
ideal platform for further incorporation of multimodal ligands. We elected to attach 4mercaptobenzoic acid, which imparts cationic and hydrophobic characteristics to the
membrane. Hofer et al. [19] provide the basis for selection of this ligand. By coupling
different thiophilic, aliphatic and aromatic ligands onto epoxide activated Fractogel® EMD,
they investigated the influence of specific molecular scaffolds and functional groups on the
overall binding properties for Immunoglobulin G (IgG) protein. Ligands with aromatic
groups such as 4-mercaptobenzoic acid significantly enhanced the binding performance of
IgG under isotonic conditions.

The objective of this research was to use graft polymerization from cellulose membrane
supports for the production of a multimodal, weak cation-exchange membrane with high
protein binding capacity at moderate-to-high ionic strength. ATR-FTIR was used to
characterize the change of surface chemistry after each modification step. To understand the
kinetics of polymer growth from the cellulose membrane surface, graft polymerization
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studies from cellulose-coated silicon substrates were done in parallel to measure the
thickness evolution of the polymer coating by ellipsometry. IgG protein was used to examine
the multimodal membranes performance, as this protein is a good model for the class of
therapeutic proteins known as monoclonal antibodies. To understand the roles that
Coulombic and hydrophobic interactions play during adsorption of the protein on the
multimodal membranes, static binding capacities were measured using protein solutions at
different pH values and ionic strengths of relevance for industrial use.

2.2 Experimental
2.2.1 Materials
Regenerated cellulose membranes with average effective pore size of 1 μm, 70-μm thickness
and 47-mm diameter were purchased from Whatman, Inc. The following chemicals were
purchased from Sigma-Aldrich with purities given in weight percent: 2-bromoisobutyryl
bromide (2-BiB, 98%), copper(I) chloride (99.99%), dimethyl sulfoxide (DMSO, 99.9%),
glycidyl methacrylate (GMA, 97%), hydrochloric acid (HCl, 37%), 4-mercaptobenzoic acid
(99%), 4-methylmorpholine N-oxide (NMMO, 50 wt.% in H2O), N,N,N′,N′′,N′′pentamethyldiethylenetriamine (PMDETA, 99%), sodium chloride (≥99%), tetrahydrofuran
(THF, anhydrous, ≥99.9%), triethylamine (TEA, ≥99%). The following chemicals were
obtained from Fisher Scientific with purities reported in weight percent: methanol (99.9%),
phosphate buffered saline (PBS) 1X powder concentrate (Biotech Grade), sodium hydroxide
(97%), tetrahydrofuran (THF, 99%), trisodium citrate dihydrate (99%).

Prior to polymerization, GMA was passed through a column of inhibitor remover (Sigma30

Aldrich, Catalog Number: 311332) to remove monomethyl ether hydroquinone. Anhydrous
THF was opened and stored in a water-free glove box. PBS buffer (25 mM, adjusted to target
pH values with HCl) was prepared from the bioreagent 1X powder concentrate and deionized
water from a Milli-Q water purification system (EMD Millipore). Poly(glycidyl methacrylate)
(PGMA) used for dip-coating silicon wafers was prepared by radical polymerization of GMA
in methyl ethyl ketone at 60°C using azobisisobutyronitrile as initiator.

Immunoglobulin G from bovine serum (IgG, ≥95%) was used as received from MP
Biomedicals, LLC. Single-side polished silicon substrates (1 cm × 3 cm) were purchased
from Nova Electronic Materials.

2.2.2 Membrane fabrication
Figure 2.1 illustrates the two-step modification procedure used to prepare multimodal
membranes. After activation of the macroporous regenerated cellulose membrane, surfaceinitiated ATRP was used to graft PGMA ‘tentacles’ from its surfaces (internal and external)
in a first step. 4-Mercaptobenzoic acid molecules were coupled to the membranes in the
second step by an epoxide ring-opening reaction. To increase measurement accuracy for the
small volumes used in each step, a larger volume of each reaction solution was prepared for
each set of 15 membranes. In the following subsections, all masses and volumes are reported
based on a per unit membrane basis, where 47 mm diameter membranes were used for the
ATRP step, and 20 mm diameter membranes were used for the 4-mercaptobenzoic acid
incorporation step.
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2.2.2.1 Membrane activation with initiator precursor
Regenerated cellulose membranes were rinsed by immersion in 10 mL of THF for 15 min
before activation. The membranes were removed from the THF, dried thoroughly, and
moved into a glove box (MBraun UNIlab, O2 < 1ppm, H2O < 1ppm) where the activation
reaction was conducted to prevent side reactions with water in the atmosphere. The activation
solution used in this study comprised an ATRP initiator precursor, 2-BiB (18 mM, 111μL),
and anhydrous THF solvent (50 mL). Membranes were placed into this solution and covered
by a specially designed Teflon cage to prevent them from being damaged by the stir bar. A
magnetic stir bar was placed on top of the cage to gently agitate the reaction mixture. The
reaction was operated at 35 ± 2ºC. After 2h, the membranes were removed from the solution
and washed by sequential immersion in 10 mL each of THF and deionized water. They were
stored in THF prior to polymerization.

2.2.2.2 Surface-initiated ATRP of glycidyl methacrylate
The ATRP reaction was conducted in the glove box to prevent catalyst oxidation. Monomer
GMA (11.37 g, 3.6 M) in an Erlenmeyer flask was de-oxygenated by purging the flask with
high purity nitrogen for 10 min and then transferred into the glove box. Copper(I) chloride
(19.8 mg, 9 mM) and PMDETA (41.8 μL, 9 mM) were added to anhydrous THF (3 mL). The
mixture was sonicated for 3 h to promote formation of the organometallic catalyst complex
and form a homogenous solution. Subsequently, monomer, anhydrous THF (7.9 mL) and the
catalyst solution were well mixed to form a grass-colored, optically clear polymerization
reaction solution. The temperature of this reaction solution was maintained at 35 ± 1ºC using
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a constant-temperature glass bead bath (ISOTEMP 145D, Fisher). Polymerization was done
in the dark, and was started once an initiator-activated membrane was placed into the
reaction solution. After a specified period of time from 20 min to 21 h, the reaction was
terminated by removing the membrane from the glove box. The PGMA-modified membrane
was washed by sequential immersion in 10 mL each of THF and dichloromethane and stored
in THF prior to multimodal ligand incorporation.

Figure 2. 1 Reaction scheme for modifying regenerated cellulose membranes with
multimodal polymer chains using surface-initiated ATRP.

2.2.2.3 Incorporation of multimodal ligands
A solution was prepared by mixing 4-mercaptobenzoic acid (77 mg, 91 mM) in 5.5 mL
methanol-water solvent (10:1 v/v), with 5 M sodium hydroxide solution (0.6 mL) and TEA
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(69.7 μL, 91 mM). One PGMA-modified membrane was placed in this mixture. The reaction
solution was heated at 65 ± 1°C with a constant-temperature aluminum bead bath
(EchoThermTM IC20, Torrey Pines Scientific). The reaction was carried out under a nitrogen
atmosphere for 18 h. The resulting multimodal membrane was taken out of the solution and
rinsed with methanol and deionized water. Membranes were stored in methanol until their
performance evaluation.

2.2.3 Kinetic study of poly(glycidyl methacrylate) growth from cellulose nanolayers
2.2.3.1. Preparation of cellulose nanolayer film on silicon wafer
Silicon wafers were washed and dip-coated with PGMA according to the method described
in the literature [10] with one modification: a 0.5 wt% PGMA solution in THF was used as
dip-coating solution.

One regenerated cellulose membrane with 47 mm diameter was placed in 7.5 mL NMMO.
To dissolve the membrane, the NMMO was heated gradually to 115°C with stirring by a
magnetic stir bar. After the formation of a transparent light-yellow solution, 2.5 mL DMSO
was added into the mixture and the temperature of the cellulose solution was brought to 50°C
for spin coating. Cellulose films were prepared by spin-coating (Laurell Technologies
Corporation, WS-650MZ-23NPPO) the cellulose solution onto the PGMA-coated silicon
wafers at 3500 rpm for 10 s. For each wafer, 1 mL of the cellulose solution was applied on its
surface using a pipette before spinning. After spin-coating, the wafers were immersed in
deionized water for 5 h to precipitate the cellulose film on the wafer surface and wash off
residual NMMO and DMSO. Finally, the cellulose-film covered silicon wafers were
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annealed at 110°C for 30 min under vacuum (6 kPa). During the annealing step, the epoxide
groups of PGMA react with some of the hydroxyl groups of cellulose film. The remaining
hydroxyl groups of the cellulose film serve as reaction sites for the subsequent surfaceinitiated ATRP step.

2.2.3.2 Surface-initiated ATRP of glycidyl methacrylate from cellulose nanolayer film
Cellulose-film coated silicon wafers were moved into the glove box and placed into an
activation solution comprising anhydrous THF (25 mL) and the initiator precursor, 2-BiB (56
μL, 18 mM). The reaction was carried out at 35 ± 2°C for 2 h. The wafer was rinsed by
successive 5 min immersions in THF, deionized water and THF and then dried with nitrogen.

PGMA was grown from initiator-activated, cellulose-film coated silicon wafers by surfaceinitiated ATRP. The following masses and volumes are based on the amounts used for one
wafer. Monomer, glycidyl methacrylate (5.78 g, 3.6 M) in an Erlenmeyer flask was deoxygenated by purging the flask with high purity nitrogen for 10 min and then moved into
the glove box. Catalyst, copper(I) chloride (9.90 mg, 9 mM), and amine ligand, PMDETA
(21 μL, 9 mM) were added into 3 mL solvent, anhydrous THF. After 3 h sonication, the
catalyst solution was mixed with monomer and another 2.5 mL of anhydrous THF inside the
glove box. Polymerization was started by placing a wafer into this reaction mixture. The
polymerization was carried out at 35°C in the dark. After a specified period of time, the
wafer was removed from the reaction solution and quenched immediately by immersion in a
solution of 0.2 M copper(II) chloride/PMDETA in THF. The wafer was washed by rinsing
with THF, dichloromethane and dried with nitrogen. After measuring the dry layer thickness
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of PGMA by ellipsometry, the wafer was put back into the ATRP reaction mixture to
continue the polymer growth until the next specified time.

2.2.4 Surface characterization
2.2.4.1 ATR-FTIR
Attenuated total-reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy was used
to obtain information on the surface chemistry of unmodified membrane, PGMA-modified
membrane, and multimodal membrane. All the measurements were performed using a
Thermo Scientific Nicolet 550 Magna-IR Spectrometer equipped with a diamond ATR
crystal. Data were processed by Omnic ESP software, Version 6.1a. Each spectrum was
collected by cumulating 16 scans at a resolution of 4 cm-1 and corrected with ATR correction
and background correction.

2.2.4.2 Ellipsometry
The dry layer thicknesses of cellulose and polymer films were measured using a multi-angle
ellipsometer (Beaglehole Instruments PicometerTM, He-Ne laser, λ= 632.8 nm). Experimental
ellipsometric data were fitted using a four-layer Cauchy model in Igor Pro 4.0.9.1 software
(Wavemetrics). Input refractive indexes of 1.455, 1.525, 1.490 and 1.525 were used for
silicon dioxide layer, PGMA dip-coated layer, cellulose layer and ATRP grafted PGMA
layer.
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2.2.5 Membrane performance evaluation
2.2.5.1 Permeability measurements
Permeability measurements of unmodified and multimodal membranes were performed using
deionized water and a 50 mL ultrafiltration cell (model 8050, EMD-Millipore). To extend the
measurement time for better precision, foil tape was used to reduce the effective diameter of
the membrane sample to 18 mm. The membrane sample was placed on a support (Whatman
114 filter paper) and loaded into the ultrafiltration cell, followed by addition of 50 mL
deionized water. A constant transmembrane pressure ranging from 20 to 62 kPa was applied
from a nitrogen cylinder. Permeate mass was measured as a function of time. Measurements
for each membrane sample were taken from highest to lowest pressure. Data reported were
averaged from three repeated measurements at each applied pressure.

2.2.5.2 Static protein binding capacity measurements
Static binding capacities were measured for Immunoglobulin G (IgG) from bovine serum on
the multimodal membranes. A typical procedure for the measurements follows: multimodal
membranes were removed from storage in methanol and dried thoroughly. Each was placed
into a 20 mL glass vial containing 2 mL of IgG solution at defined concentration in binding
buffer (25 mM phosphate buffered saline). Initial IgG concentrations were from 0.5 to 5
mg/mL for the adsorption isotherm experiments, and 5 mg/mL in all other static binding
experiments. The vials were incubated in a shaker bath (22°C, 100 rpm) for 20 h, which was
determined by experiment to be enough time to reach equilibrium. The equilibrium
concentrations of IgG solutions were measured by UV-Vis spectrophotometer (Cary 50 Bio
UV-Vis spectrophotometer) at 280 nm. A calibration curve prepared in this study was used to
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translate the UV absorbance into concentration. A mass balance involving initial and
equilibrium concentrations was used to calculate binding capacities, reported as the total
adsorbed IgG mass per unit volume of membrane.

To investigate the optimum pH conditions for the IgG loading under different salt
concentrations, solution pH was adjusted with HCl to values of 5.00−7.10. To investigate the
effect of ionic strength and salt type, sodium chloride and sodium citrate were used to adjust
the solution ionic strength up to 1.6 M (for NaCl) or 1.0 M (for sodium citrate).

2.3 Results and discussion
Our group and others [8-18] have demonstrated that surface-initiated ATRP can be used to
graft polymer chains from membranes pore surfaces in controllable ways. In this study,
polymerization time was used as an independent variable to graft controlled amounts of
PGMA from macroporous cellulose membranes. The membranes were modified further by
reaction with 4-mercaptobenzoic acid to produce multimodal membrane adsorbers with high
binding capacity and exceptional salt-tolerance.

2.3.1 Characterization of membrane surface chemistry
Surface chemistry properties of the membranes were analyzed by ATR-FTIR to support
successful membrane surface modification. Figure 2.2 presents ATR-FTIR spectra of
unmodified (spectrum A), PGMA-modified (spectrum B), and multimodal (spectrum C)
membranes. Compared with spectrum A, spectrum B has a significant absorption peak
around 1730 cm-1 that is assigned to stretching of carbonyl groups in PGMA. This peak
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indicates successful surface-initiated ATRP modification. In spectrum C, peaks around 1600
cm-1 and 1400 cm-1 are assigned to carboxylate groups within the multimodal membranes.
The peak observed around 1550 cm-1 is assigned to di-substituted aromatic groups. These
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peaks indicate successful ligand incorporation.
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Figure 2. 2 ATR-FTIR spectra: (A) unmodified membrane, (B) PGMA modified membrane,
and (C) multimodal membrane.

To examine membrane stability following treatment with common caustic cleaning and
sterilization solutions, we soaked the modified membranes 0.3 M NaOH solution for 15 min
and then compared ATR-FTIR spectra of membranes before and after this challenge. There
were no changes in the spectra, suggesting that the membranes are stable.
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2.3.2 Membrane performance properties
Performance metrics used in this work to characterize this new class of adsorptive
membranes include permeability and static binding capacities for a model antibody protein
under varied pH and ionic strength values.
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Figure 2. 3 Permeability measurements for unmodified membranes, initiator-activated
membranes, and multimodal membranes. Surface-initiated ATRP was done for times ranging
from 20 min to 21 h to prepare the multimodal membranes.

2.3.2.1 Permeability measurements
Permeability measurements were used to evaluate the transport properties of unmodified
membranes and multimodal membranes. Figure 2.3 shows permeability versus pressure data
for unmodified membranes, initiator-activated membranes, and multimodal membranes
prepared using different polymerization times (20 min, 40 min, 1 h, 2 h, 4 h, 21 h). The
uncertainties reported in Figure 2.3 represent the standard deviations among three repeat
measurements for each
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test condition. The permeabilities of unmodified and activated membranes are similar and
higher than the permeabilities of polymer-modified membranes, which is consistent with
previous reports [10,14]. Within the set of multimodal membranes, permeability decreased in
a regular fashion as polymerization time increased and was reduced by 30% after the longest
polymerization time studied. This result further supports successful grafting of the
multimodal polymer chains from the membranes pore surfaces, which reduces the average
effective pore size. We also noticed that the permeability decreased 10−20% as applied
pressure increased to the highest value that was tested. This result indicates that membrane
compaction occurred in the range of studied pressure and places practical limitations on flow
rates that may be used without reinforcement of the base material. In practice, manufacturers
of commercial ion-exchange membranes based on regenerated cellulose use stabilized
reinforced cellulose.

2.3.2.2 Dependences of static binding capacity and PGMA thickness on polymerization time
PGMA-modified membranes provide an ideal platform for incorporation of the multimodal
ligands. A large stoichiometric excess of 4-mercaptobenzoic acid was used in the multimodal
membranes preparation. Therefore, the degree of PGMA polymerization, and, thus,
polymerization time determines the number of potential protein binding sites on the
multimodal membranes. Figure 2.4 shows that static binding capacity of the multimodal
membranes increases as polymerization time increases. However, it approaches a plateau
value of about 124 mg/mL. Potential reasons for such behavior have been discussed in our
previous work [11]. For the multimodal membrane prepared here, we hypothesize that this
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behavior is due to a slowing down of polymer growth, as the permeability for the longer
polymerization times (2, 4, 21 h) are all similar, shown in Figure 2.3.

To further understand the cause of the plateau behavior, a kinetic study was done to
determine the thickness evolution of the PGMA layer using cellulose-coated silicon
substrates. Unlike the work done previously by our group, we adopted a new methodology
for these measurements in which we coated the silicon substrates with cellulose nanolayers
using the strategy outlined by Wågberg and colleagues [20-22] with some modifications.
Instead of using poly(ethyleneimine) (PEI) as the anchoring polymer layer, PGMA was used
to bind covalently to both the silicon oxide wafer and the cellulose nanolayer. This enables
the cellulose nanofilm to be used as a model surface for ATRP reactions over a broader range
of reaction conditions. The cellulose film prepared from NMMO solution has been shown to
possess a cellulose II polymorph [20], the same polymorph as regenerated cellulose in the
base membranes. Matching the polymorphs of the cellulose nanolayers and membranes
allows us to use the kinetics results directly in meaningful ways to design better membranes.

In this kinetics study, cellulose dry layer thickness was measured by ellipsometry to be 22±
0.5 nm. After initiator activation by reacting with 2-BiB, the dry layer thickness increased to
23±0.5 nm, consistent with mass addition to the layer. Figure 3 also shows the dependence
of PGMA thickness on polymerization time. The polymer grew dramatically within the first
4 h. As polymerization increased, the growth rate decreased and finally approached a plateau
value of about 70 nm. The thickness evolution follows the same trend as static IgG binding
capacity, which indicates that the degree of polymer growth from the membrane affects the
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static IgG binding capacity of the multimodal membranes. Noteworthy is that IgG binding
capacity does not increase in linear proportion to the PGMA thickness. Thus, the plateau in
static IgG binding capacity appears to be related in part to steric hindrance from pore filling
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Figure 2. 4 Dependences of membrane static IgG binding capacity and PGMA layer
thickness on surface-initiated ATRP time. All membranes were prepared by incorporating 4mercaptobenzoic acid at 65°C. The error bars in binding capacity data represent a
combination of the system uncertainty and standard deviation in the measurements between
two batches of membranes. The error bars in PGMA layer thickness represent the standard
deviation among three measurements.

To evaluate the ligand incorporation, a PGMA-modified surface was reacted with a large
excess of 4-mercaptobenzoic acid. Layer thickness increased from 44 ± 0.9 nm to 81 ± 2.6
nm as a result of ligand incorporation, which is caused by an increase of the molecular
weight of the surface-anchored polymer chains. Upon reaction, the molecular weight of a

43

repeat unit of the polymer increases from 142 g/mol to 296 g/mol. In addition, the density of
the polymer film increases from 1.1 g/cm3 to roughly 1.2 g/cm3. Using these data and
following the analysis of Biesalski and Ruhe[23], we determined that the fractional
conversion of epoxide groups to ligand was greater than 91%.

2.3.2.3 Dependence of static binding capacity on pH
The pH of the protein solution affects the charge of the protein and the membrane surface,
and, thus, determines the extent of Coulombic interactions between the membrane and the
protein.
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Figure 2. 5 Influence of pH on static IgG binding capacity for multimodal membranes
prepared by 21 h surface-initiated ATRP and 4-mercaptobenzoic acid incorporation at 65°C.
The tests were conducted at pH values above and below the pI of IgG at three sodium chlorid
concentrations (0, 150 and 300 mM). The concentration of IgG was 5 mg/mL.
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The isoelectric point of IgG is in the range 6.4−8.5, while the pKa value for the carboxylic
acid group on 4-mercaptobenzoic acid is 4.80. The test pH range for IgG binding to the weak
cation multimodal membranes was set to be 5.0−7.5, within which IgG was charged
positively and the membrane was charged negatively. Figure 2.5 shows the influence of pH
on static IgG binding using the multimodal membranes. The error bars reported in Figure 4
represent the combined uncertainty of the measurements, which include the standard
deviation of measurements from two membrane batches and the instrumentation
measurement uncertainties. Very high binding capacities for IgG occur near pH = 6.5, even
at 300 mM ionic strength. At lower pH, the static binding capacities decrease significantly as
the carboxylic groups on the multimodal membranes become partially to fully protonated.
Given the pKa of 4.80 for 4-mercaptobenzoic acid, it might be unexpected to see the binding
capacity decreasing at pH 5.9. However, it is not uncommon for the acidity constant of a
polymeric organic acid to be different from its corresponding monomer value due to the
change of chemical environment in the polymer. For example Qian and coworkers [24] found
the predicted pKa values for the dimer and trimer of methacrylic acid are higher by about 0.8
pKa units than the monomer value. Thus, even though IgG is positively charged at these low
pH conditions, the interactions between the membranes and IgG decrease due to protonation
of the acid groups on the membrane. Hydrophobic and/or hydrogen bonding interactions can
explain why the membrane retains low capacity at lowest pH values studied. The static
binding capacities also decreased at higher pH as IgG becomes less positively charged. Our
results are consistent with the common practice to adjust the pH to 0.5−1 pH units below the
pI of the target protein to achieve good performance using cation exchangers.
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2.3.2.4 Dependence of static binding capacity on IgG concentration
For static adsorption isotherm measurements, IgG solutions were prepared in 25 mM PBS
buffer and pH was adjusted to the optimum pH of 6.5. Figure 2.6 shows the IgG adsorption
isotherms under the three different NaCl salt conditions (0 mM, 150 mM and 300 mM). We
are interested in 150 mM and 300 mM salt concentrations, as they are consistent with elution
conditions used in Protein A chromatography [25,26], the initial chromatography step in
purification of monoclonal antibodies. (Our cationic multimodal membranes likely would
find application as the step following Protein A chromatography.) Within IgG concentration
test range (initial concentrations ranging from 0.5 mg/mL to 5 mg/mL), the static binding
capacities increased with increasing IgG concentration.

Experimental data were fitted to the Langmuir adsorption model to evaluate the association
coefficients and maximum binding capacities. Table 2.1 summarizes the results. The
association coefficient decreased with increasing salt concentration as charge screening
interferes with the adsorption of protein through Coulombic interactions. Although the
maximum binding capacity decreased with increasing ionic strength, the multimodal
membranes retained 94% and 80% of their maximum binding capacities at 150 mM and 300
mM ionic strength. This represents a significant improvement in salt-tolerance compared
with traditional ion exchangers. This significant improvement agrees with our expectation
that increasing hydrophobic interactions compensate for decreasing Coulombic interactions
at higher ionic strength.
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Figure 2. 6 Adsorption isotherms for IgG at 22°C and three sodium chloride concentrations
(0, 150 and 300 mM). The multimodal membranes were prepared by 21 h surface-initiated
ATRP and 4-mercaptobenzoic acid incorporation at 65°C. Symbols represent experimental
data, and curves represent best fits using the Langmuir adsorption model Table 1 summarizes
the model parameters.

Table 2. 1 Langmuir adsorption model parameters.
Salt
concentration
(mM)
0
150
300

Association
Coefficient
(mL/mg)
2.06 ± 0.47
1.07 ± 0.10
1.07 ± 0.16

Maximum
binding capacity
(mg/mL)
150.7 ± 9.2
141.2 ± 4.7
121.8 ± 6.5

2.3.2.5. Dependence of static binding capacity on ionic strength and salt type
As demonstrated in the isotherm measurements, ionic strength is an important factor that
affects the interaction between membrane adsorbers and the target protein. With the
multimodal membranes prepared in this research, Coulombic interactions and hydrophobic
interactions take place during the protein adsorption. However, the effect of ionic strength on
these two interactions is different. Coulombic interactions generally decrease as increasing
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salt concentration while hydrophobic interactions depend on salt type [27,28]. Kosmotropic
salts promote hydrophobic interactions, whereas chaotropic salts reduce hydrophobic
interactions. We therefore anticipated the multimodal membrane to exhibit salt-tolerant
binding behavior. To investigate the effects of salt on the binding capacity of the protein,
high values of ionic strength were tested with 5 mg/mL IgG solutions at pH 6.5. Figure 6
shows the effect of solution ionic strength (adjusted using sodium chloride and sodium citrate)
on static IgG binding to the multimodal membrane. Static binding capacities of IgG were
measured in NaCl solutions with ionic strengths up to 1.6 M and sodium citrate solutions
with ionic strength up to 1.0 M, beyond which IgG started precipitating from solution.
Sodium chloride was chosen as a ‘neutral’ salt, as it acts neither as a kosmotrope or
chaotrope. In Figure 6, as NaCl concentration increases, the static IgG binding capacity
decreases and eventually approaches a plateau value of 47 mg/mL. We also tested sodium
citrate, a salt used conventionally in elution buffers for Protein A chromatography [26].
Figure 2.7 shows that the static IgG binding capacity decreases by only ~10% from the
lowest to highest ionic strength conditions using sodium citrate. As it turns out, sodium
citrate is a kosmotropic salt. As a result, increasing the concentration of sodium citrate in the
protein solution appears to enhance hydrophobic interactions between the membrane and the
protein. This enhancement in hydrophobic interactions compensates for the loss of
Coulombic interactions as ionic strength increases. Thus, within the wide range of ionic
strengths studied (0 to 1 M), the citrate salt has only a minor effect on the IgG binding
capacity.
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Figure 2. 7 Influence of ionic strength on static IgG binding capacities for multimodal
membranes prepared by 21 h surface-initiated ATRP and 4-mercaptobenzoic acid
incorporation at 65°C.
Development of a membrane that can achieve such high capacities at these ionic strengths is
a major breakthrough, since traditional ion-exchange column would fail at these
conditions[29]. Dynamic testing is needed to confirm that the membranes maintain high
capacity during flow, which is expected from our early work [30] with ion-exchange
membranes. But on first look, this multimodal membrane is a promising candidate to replace
the tradition cation exchangers used after the Protein A chromatography step used in the
purification of monoclonal antibodies.

2.4 Conclusions
A new multimodal membrane was developed for chromatographic bioseparations that
comprises a thin, grafted polymer coating on a macroporous cellulose substrate. Permeability
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and protein (IgG) binding capacity measurements show that polymerization time can be used
to achieve high binding capacity while maintaining adequate permeability of the membrane.
Kinetic studies with a model cellulose nanolayer suggest that the degree of polymer grafting
directly affects the static binding capacity of the multimodal membrane. Steric protein
exclusion from potential binding sites is also limit the IgG binding capacity on the
multimodal membrane. Measured equilibrium IgG binding capacities using protein solutions
at different pH values and ionic strength values demonstrate that both Coulombic and
hydrophobic interactions occur between the protein and the membrane. Characteristic of
multimodal adsorbers, the multimodal membranes maintain significant binding capacities in
excess of 90 mg IgG/mL at ionic strength values that are typical for elution buffers used in
multi-stage bioseparation processes. For sodium citrate, a conventional salt used in elution
buffers of Protein A columns, increasing ionic strength had only a minor effect on the IgG
binding capacity. These results indicate that the newly developed multimodal membranes
have great potential to compete with more traditional cation-exchange materials following
the Protein A purification step in the downstream processing of antibody products.

To further investigate the utility of these cation-exchange multimodal membranes in mAb
purification operations, it will be necessary to develop effective elution strategies and to
quantify dynamic binding capacity and selectivity. Adjusting pH and adding chaotropic salts
or displacers are promising approaches to be considered for elution of IgG from the
multimodal membranes. Recently, Nadarajah and Mehta [31] used an overload and elute
method with multimodal cation exchangers to produce a highly purified mAb product. Their
work indicates that it should be possible to design processes using the new cation-exchange
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multimodal membrane materials that provide good selectivity for mAbs over solution
impurities.
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Chapter Three

A NEW MULTIMODAL MEMBRANE ADSORBER FOR MONOCLONAL ANTIBODY
PURIFICATION
[As published in Journal of Membrane Science, 492(2015) 137-146, with minor
modifications]

3.1 Introduction
Excellent separation resolution and mild operating conditions make chromatographic
processes particularly useful in downstream protein purification operations. However,
substantial improvements in downstream manufacturing processes are necessary to increase
production capacities and meet the large, rapidly increasing demand for protein therapeutics.
While the conventional chromatographic operations are designed to purify protein based on a
single interaction mode such as affinity interaction, Coulombic interaction, hydrophobic
interaction and size exclusion [1,2], multimodal chromatographic operations are used to
purify protein through two or more orthogonal modes of interaction. Multimodal adsorbents
have been shown to improve product quality by removal of high molecular weight aggregates
and can improve process efficiency in industrial-scale mAb drug manufacturing [3-5].
Specifically, the advantage of multimodal operations is that they may decrease the number of
purification steps, thereby shortening purification times and increasing the overall protein
yields. These factors are paramount in controlling overall manufacturing capacity and protein
product quality.

Most commercial multimodal chromatographic media comprise resin beads functionalized
with ligands that exhibit both hydrophobic and Coulombic properties. Exceptions are the
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commercial membranes from EMD-Millipore (Chromasorb) and Sartorius (Sartobind STIC®
PA Nano); however, these are limited to anionic MMMs. The use of resin beads as packing
media results in low productivity[6-8]. Consequently, the use of membranes has become a
viable option for membrane chromatography, particularly now that strategies have been
developed by our group and others to increase the binding capacities of membrane adsorbers
to values that meet or exceed the corresponding resins [9-11]. Just recently, we described the
use of surface-initiated atom transfer polymerization to prepare the first cationic multimodal
membrane [10].

Given the promising application of multimodal membrane adsorbers for protein bind-andelute purifications, detailed theoretical simulations of protein binding on multimodal
membrane adsorbents are needed to reduce the time and cost spent on process development.
While the well-known Langmuir isotherm model used to describe convex isotherms does
provide the apparent maximum binding capacity and association coefficient, it does not
provide mechanistic insights on the influence of different interaction types and the mobile
phase conditions on protein binding, and its constants must be adjusted for each new set of
operating conditions. In attempts to overcome such limitations, Brooks and Cramer [12]
developed the Steric Mass Action (SMA) formalism model, which entails the use of three
parameters for determining the non-linear adsorption in an ion-exchange system. This SMA
model considers the steric hindrance of salt counterions, but not the protein-protein
interactions. Mollerup et al. [13] extended SMA to develop a thermodynamic model that
includes interaction-type parameters, and applies to both hydrophobic interaction
chromatography and ion exchange. Using the generalized framework developed by Mollerup
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et al., Ottens and coworkers [14] developed a model for protein adsorption on multimodal
adsorbents functionalized with ligands carrying both hydrophobic and groups. This model
has not yet been applied to membrane adsorbers.

The objectives of this study were to apply the thermodynamic model described by Ottens and
coworkers [11] to analyze immunoglobulin G (IgG) adsorption on our newly developed
multimodal membrane adsorbers and to evaluate membrane performance under static and
dynamic protein binding conditions. Fitted model parameters were used to elucidate the
protein adsorption mechanism(s) under different salt conditions (type and ionic strength).
IgG dynamic binding capacities and load productivities were measured for comparison with
commercial products. Using column studies, we determined the effects of flow rate and ionic
strength on the dynamic binding capacities, identified the rate limiting factors for protein
binding on the new MMM, and developed an effective elution strategy.

3.2 Theory
Ottens and coworkers [14] developed a thermodynamic model for protein adsorption on
multimodal adsorbents and an approach for estimating the unknown model parameters. The
stoichiometric exchange of protein and hydrophobic ligands with salt counterions is
represented by the following reaction:
𝑃 + 𝑣𝑣𝑣 + 𝑛𝑛 ⇔ 𝑃𝑃𝑛 + 𝑣𝑣

where a protein molecule P is adsorbed to a stationary phase with n hydrophobic ligands and
simultaneously exchanges with v salt counter-ions to form the protein-ligand complex PLn. v
is defined as the ratio of the binding charge of the protein zp to the charge of the salt
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counterion zs: 𝑣 = 𝑧𝑝 ⁄𝑧𝑠

In multimodal exchange chromatography, the general form of the single component isotherm
is given by Equation 1 [14]:
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where qp and cp are the protein concentrations in the adsorbed phase and liquid phase; 𝑞𝑝,𝐼𝐼𝐼

𝑚𝑚𝑚
and 𝑞𝑝,𝐻𝐻𝐻
are the maximum binding capacities achieved through Coulombic interaction and

�𝑒𝑒 is the thermodynamic equilibrium constant; cs is the salt
hydrophobic interaction; 𝐾

concentration in the liquid phase; c is the molarity of the solution in the pore volume; 𝛾�𝑝 is the
normalized activity coefficient; 𝛬𝐼𝐼𝐼 is the ionic-exchange ligand density; and 𝛬𝐻𝐻𝐶 is the

hydrophobic ligand density.

Ottens and coworkers [14] point out for the case of multimodal adsorbents bearing the same
number of Coulombic interaction groups and hydrophobic interaction groups that 𝛬𝐼𝐸𝐸 =
𝛬𝐻𝐻𝐻 = 𝛬, and the adsorption isotherm simplifies to Equation 2:
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The asymmetric activity coefficient is expressed by the following activity coefficient model:
𝛾�𝑝 =

𝛾𝑝
∞,𝑤
𝛾𝑝

= exp(𝐾𝑠 𝑐𝑠 + 𝐾𝑝 𝑐𝑝 )

(3)

where Ks and Kp are interaction constants. Ks is proportional to the difference of
intermolecular attractive forces between protein-water and protein-salt, and Kp is
proportional to the difference of intermolecular attractive forces between protein-water and
protein-protein [10].
Combining Equations 2 and 3 yields the single component adsorption isotherm:
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where A is the initial slope of the isotherm or the partition coefficient in the limit qp→0.
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In previous studies of resin columns [13-15], the parameter A was estimated from isocratic
retention data under varying salt concentrations. This method is based upon Ettre’s definition
of the retention factor [16], which considers that part of the solute retention time is due to
pore diffusion within the resin beads. This method is limited to the estimation of A for salts
that can be used as elution modulators. However, in the case of our MMM adsorbers, not all
salt types can be used as elution modulators, and convection dominates the mass transport of
protein within the MMM. To overcome this limitation, we used the Langmuir isotherm
model to estimate parameter A:
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where A represents the initial slope of the isotherm.

Ottens and coworkers provide a detailed account of their methods to fit the isotherm
parameters, which include linear regression and constrained minimization [14]. Here,
however, we used minimization algorithms from the pyOpt 1.1.0 optimization tool to
estimate the parameters providing the best fit of the models to the data [17].
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(6)

3.3 Experimental
3.3.1 Materials
In our experiments we used regenerated cellulose membranes with a 1.0 µm average
effective pore size, a 70 µm thickness and a 47 mm diameter, which we purchased from
Whatman, Inc. The following chemicals were purchased from Sigma-Aldrich with purities
given in weight percentage: 2-bromoisobutyryl bromide (2-BiB, 98%), copper(I) chloride
(CuCl, 99.99%), glycidyl methacrylate (GMA, 97%), guanidine hydrochloride (Gua-HCl, ≥
99.9%), hydrochloric acid (HCl, 37%), hydrochloric acid 0.01 M standard solution, 4mercaptobenzoic acid (99%), N,N,N’,N”,N”-pentamethyldiethyldiethylenetriamine
(PMDETA, 99%), phenolphthalein (0.5% solution), sodium chloride (NaCl, ≥99%), sodium
citrate (≥ 99%), sodium hydroxide 0.01 M standard solution, sodium thiocyanate (NaSCN, ≥
98%), tetrahydrofuran (THF, anhydrous, ≥99.9%), urea ( ≥98%). The following chemicals
were obtained from Fisher Scientific with purities reported in weight percentage: methanol
(99.9%), phosphate buffered saline (PBS) 1X powder concentrate (Biotech Grade), sodium
hydroxide (97%), tetrahydrofuran (THF, 99%), trisodium citrate dihydrate (99%).

Three buffers were used in the protein dynamic binding experiments. A stock solution of 25
mM PBS was prepared using deionized water from a Milli-Q water purification system
(EMD Millipore). The pH of this PBS buffer was adjusted with HCl to 6.5 and used as the
binding buffer (B). The elution buffer (E1) for dynamic binding experiments was prepared by
adding 1M sodium thiocyanate into 25 mM PBS buffer without pH adjustment. The
regeneration solution (E2) was 6M Gua-HCl in water.
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3.3.2 Membrane surface modification
The new multimodal membranes were prepared using the surface-initiated ATRP technique,
as detailed in our previous publication [10]. We first modified regenerated cellulose
membranes via surface-initiated ATRP of poly(glycidyl methacrylate) ‘tentacles’. Next, an
epoxide ring-opening reaction was used to couple 4-mercaptobenzoic acid to the membranes.
The details of reaction conditions and times were described previously [10].

3.3.3 Ligand density measurement
A colorimetric titration method was used to determine the ligand density. Specifically, the
carboxylate groups on the MMMs were protonated via immersion of a known volume of
MMMs in 10 mL (VHCl) of standardized 0.01 M (c0) hydrochloric acid solution, and
incubated in a shaker bath (22 °C, 100 rpm) for 30 min. They were then removed from the
hydrochloric acid solution, which was titrated with a standardized 0.01 M sodium hydroxide
solution (VNaOH). Equation (7) was used to determine the ligand density:
𝐿𝐿 =

𝑐0 (𝑉𝐻𝐶𝐶 −𝑉𝑁𝑁𝑁𝑁 )

(7)

𝜀𝑉𝑚

where ε is the porosity of the MMM and Vm is its volume (for a single piece of 18 mmdiameter membrane, ε = 0.8 and Vm is 0.018 mL).

3.3.4 Roles of salt type and ionic strength on IgG adsorption isotherms
Immunoglobulin G (IgG) from bovine serum was used to measure equilibrium binding
capacities of MMMs. We used three salts to determine their effects on IgG adsorption
isotherms: sodium citrate, sodium chloride and sodium thiocyanate (representatives of
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kosmotropic, ‘neutral’ and chaotropic salts). Specifically, 25 mM PBS buffers with different
concentrations of each salt type and IgG were prepared, and HCl was used to adjust the pH of
each solution to 6.5. The multimodal membranes cut into 18 mm-diameter discs were
preconditioned with 25 mM PBS buffer at a pH of 6.5 and then rinsed with methanol and
dried with nitrogen gas.

Twenty-four MMM samples were used to measure IgG isotherms for each salt type.
Isotherms (each composed of six datum points) were measured at four salt concentrations (0
M, 0.15 M, 0.3 M, 0.45 M). Protein binding capacities were obtained by contacting 2 mL of
protein solution at defined initial concentrations with one 18 mm-diameter membrane in 20
ml glass vials and measuring the protein concentration in the liquid phase after equilibrium
had been reached. Six initial protein concentrations ranging from 0.5 to 5 mg IgG/ml were
used to obtain complete adsorption isotherms. The vials were agitated in a shaker bath (22
°C, 100 rpm) for 20 h. A Cary 50 Bio UV-vis spectrophotometer was used to measure IgG
concentrations at 280 nm. The binding capacities, reported as the adsorbed mass of protein
per unit dry volume of membrane, were calculated by mass balance with the initial and final
concentrations of protein solution derived from a calibration curve. The membranes were
regenerated with 1 M NaSCN solution for reuse.

3.3.5 Elution studies
The MMMs were loaded with 3 mg IgG/ml solution at pH = 6.5 via equilibrium binding
experiments as described in Section 3.4. After loading, the MMMs were immersed in binding
buffer B and agitated in a shaker bath (22 °C, 100 rpm) for 10 min to remove any unbound
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IgG. Subsequently, MMMs were transferred into different elution buffers and UV
absorbance at 280 nm for all elution solutions was recorded at 2 h and 23 h. Three different
elution strategies were investigated. The first set of elution buffers was prepared by adjusting
pH of the binding buffer to values ranging from 3.9 to 9.7 using HCl or NaOH. The second
set of elution buffers was prepared by adding 1-3 M urea in the binding buffer. The third set
of elution buffers was prepared by adding 0.5-1.5 M salt (NaSCN and NaCl) in the binding
buffer.

3.3.6 Kinetic binding study
A solution of 3.0 mg IgG/ml was prepared in 25 mM PBS buffer with a pH of 6.5. Each
membrane was preconditioned as described in Section 3.4, then placed into a 20 mL glass
vial and contacted with 2 mL of the protein solution in a shaker bath (22 °C, 100 rpm) for up
to 26 h. The membranes were removed from the protein solution at defined times, and
protein concentrations were measured by UV adsorbance at 280 nm. The adsorbed mass was
calculated by mass balance as described in Section 3.4.

3.3.7 Dynamic protein binding capacity
An AKTA Purifier 100 system was used to measure the dynamic adsorption capacities of
MMMs, which were equilibrated with 25 mL buffer B for 15 min at room temperature prior
to loading into a membrane chromatography module. A stack of 6 MMMs was placed in a
Mustang Coin® module (Pall Corporation) with one piece of 25 µm nominal pore diameter
filter paper (Whatman 5) placed on each side of the stack. The overall bed volume was 0.136
mL. The bed void volume was determined by injecting 1M NaSCN solution into the module
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with no membranes and with membranes. The volume where the conductivity began to
increase was recorded. The difference in these volumes represents the void volume of the
membrane bed, which was found to be 0.114 mL. Thus, the bed void fraction was 0.84
slightly higher than the individual MMM void fraction of 0.8.The module was inserted in the
AKTA purifier. Except for the specifically noted steps, a flow rate of 1 ml/min (10 column
volumes/min) was used during the dynamic binding capacity measurements. Buffer B was
used to equilibrate the membrane bed until a stable baseline was observed via UV detection
at 280 nm. Eighteen milliliters of protein solution (3 mg IgG/mL in buffer B, prefiltered with
a VWR 0.2 µm cellulose acetate syringe filter) was injected at flow rates ranging from 0.1 to
0.5 ml/min (1 to 5 column volumes/min). Unbound protein was washed from the membrane
column with 10 mL buffer B. Fifteen milliliters of buffer E1 was then pumped through the
membrane column. Finally, the membrane was regenerated with 5 mL of 6 M Gua-HCl
solution. In-line UV, pH and conductivity detectors were used to monitor the effluent from
the membrane column continuously. A pressure transducer installed in the AKTA system
was used to measure the pressure drop across the membrane column. All the data were
collected, viewed and analyzed by Unicorn 5.11 software (GE Healthcare, Bio-Sciences).

3.3.8 Ionic strength effect on dynamic binding capacity
The procedure described in Section 3.7 was used to determine how the MMM binding
capacities were affected by ionic strength, which was varied by adding NaCl into binding
buffer B. The flow rate during loading was 0.1 ml/min. The binding buffers adjusted to a pH
of 6.5 were prepared with 0, 150, and 300 mM NaCl. The protein solutions (3 mg IgG/ml)
were prepared with each of the binding buffers.
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3.4 Results and Discussion
3.4.1 Multimodal adsorbent comparisons
Three commercial multimodal resins were used to compare their performances with the new
MMM: CaptoTM MMC (2-benzamido-4-mercaptobutanoic acid) and CaptoTM MMC ImpRes
from GE Healthcare and MBI HypercelTM (2-mercapto-5-benzimidazolesulforic acid) from
Pall Corporation. Fig. 3.1 depicts the ligand structures of the multimodal materials. Table 3.1
compares the performance characteristics. The ligand density of the MMM determined by
titration was substantially higher than the ligand densities of the resins, as was the resulting
protein binding capacity. Both were higher because the surface-initiated ATRP technique
creates a 3-dimensional scaffold comprising a high density of grafted polymer chains with
accessible protein binding sites. As noted in Table 3.1, the load productivity for the MMM is
also higher than the maximum load productivity for resins, indicating that the MMM column
is able to process a larger volume of feed solution in a defined timeframe. The reported load
productivity for the MMM is the value measured at the highest flow rate that was studied.
Thus, it is a conservative estimate of the achievable productivity. The load productivity
advantage originates from the rapid mass transport of the protein molecules from the solution
to the binding sites by convective flow within the macropores of MMM [18]. Table 3.1 also
compares the residence times for the MMM and CaptoTM MMC ImpRes at equivalent DBC.
The residence time for the MMM is an order of magnitude lower than the resin under
conditions that yield the same DBC. This result is important because lower residence times
improve productivity and protein product quality. Finally, Table 3.1 shows that the MMM
maintains high capacity under salt conditions where the resin products fail.
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(a)

(b)

(c)

Figure 3. 1 (a) Multimodal Membranes (MMM) developed in our group [7]; (b) MBI
HypercelTM from Pall Life Science, NY, USA; (c) CaptoTM MMC from GE Healthcare, NJ,
USA.
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Table 3. 1 Comparison of performance characteristics of the new MMM and commercial
MMC resins.
Chromatography
Medium
MMM
MEP HyperCelTM
CaptoTM MMC

Average
Ligand
Density
(mmol/L)
340±24
80-125
80

IgG Static
Binding
Capacity
(mg/ml)
180
N/A
70

IgG Dynamic
Binding
Capacity*
(mg/ml)
56
20
N/A

Load
Productivity
(mg/ml/min)
12±2
5
n/a

3.4.2 Salt effect on adsorption isotherms for the MMM
Salt type and salt concentration are two important factors that influence protein adsorption on
multimodal chromatographic adsorbents. Previously, we found that the MMMs exhibit
excellent salt tolerance (i.e., maintain high protein binding capacity in the presence of sodium
chloride), resulting from the combination of Coulombic and hydrophobic interactions [10].
In this study, IgG adsorption isotherms were measured with three different types of salts at
four different ionic strengths of practical relevance (Fig.3.2).
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Figure 3. 2 Roles of ionic strength and salt type on adsorption isotherms for IgG at 22 °C: (a)
sodium citrate, (b) sodium chloride, (c) sodium thiocyanate, (d) Langmuir model association
constant. The multimodal membranes were prepared by 21 h surface-initiated AT RP and 4mercaptobenzoic acid incorporation at 65 °C. Symbols represent experimental data, and
curves represent best fits using the Langmuir adsorption model. The error bars in IgG static
binding capacities represent the standard deviation of two measurements, while the error bars
in association coefficient indicate the standard deviation from nonlinear regression.
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500

Fig. 3.2 (a) shows the results using sodium citrate, a kosmotropic salt that can promote
hydrophobic interactions between protein molecules and the MMM. As ionic strength
increased from 0 to 450 mM, the maximum binding capacity decreased from 177 mg/ml to
150 mg/ml. There appears to be a minimum in capacity at an intermediate ionic strength of
300 mM; however, at the 95% confidence interval the data for 300 mM and 450 mM are not
different. These data can be explained by considering that Coulombic protein-ligand
interactions predominate at low salt concentrations and become less important at high ionic
strength due to charge screening effects. Kosmotropic salts can enhance hydrophobic
interactions; thus, increasing sodium citrate concentration leads to stronger hydrophobic
protein-ligand interactions. Because of the opposite trends in Coulombic and hydrophobic
interactions with ionic strength, it is reasonable to expect that there is some intermediate salt
concentration at which a minimum protein binding occurs.

Sodium thiocyanate, which is a strong chaotropic salt, diminishes hydrophobic interactions
while simultaneously disrupting Coulombic interactions by charge screening. Fig. 3.2 (c)
shows that the IgG binding capacity decreased by nearly 66%, from 177 mg/ml to 61 mg/ml,
as ionic strength increased from 0 to 450 mM. Fig. 3.2 (b) shows that a moderate effect of
ionic strength on protein binding was observed for sodium chloride (neither a kosmotrope or
a chaotrope), with a 40% decrease in IgG binding capacity from the lowest to the highest
ionic strength.

A general finding is that, relative to traditional ion-exchange media [19], the MMM
maintains very high protein binding capacities in the presence of salt at ionic strength values
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that are typical for elution buffers used in multi-stage antibody purification process. For
sodium citrate, a conventional salt used at 150-300 mM ionic strength in elution buffers of
Protein A columns, the results indicate that the MMMs are a better choice than traditional
cation-exchange materials following the Protein A purification step in the downstream
processing of antibody products.

The experimental adsorption isotherm data were fit with Langmuir adsorption model. In Fig.
3.2 (d), the association coefficient K (and the parameter describing maximum capacity, qmax)
decreases from kosmotropic to chaotropic salts for reasons explained above. While the
Langmuir model described these constant-pH isotherm data well, there is no clear correlation
to describe how K (or qmax) changes with ionic strength. Thus, the Langmuir model is illsuited for predicting the adsorption behavior under non-test salt conditions.

3.4.3 Thermodynamic modeling applied on the MMM
The thermodynamic model introduced in Section 2 was used to describe experimental data
for the IgG adsorption isotherms on MMM (Fig. 3.3), and a unique set of physically
meaningful parameters was regressed to describe binding for all test conditions using a
specific salt type (Table 3.2). Unlike parameters in the Langmuir model, these parameters are
independent of ionic strength.

Using the globally regressed parameters, the model correctly describes how IgG binding
capacity decreases with increasing salt concentration in all these cases, except for sodium
citrate (Fig. 3.3a). While it is clear that Coulombic interactions play an important role for the
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NaCl and NaSCN systems, a close examination of the isotherm parameters in Table 3.2
shows that both v and n are non-zero in all cases, indicating the occurrence of both
Coulombic and hydrophobic interactions between IgG and the MMM in all systems. The
model-derived isotherms for the sodium citrate system show almost no dependence on ionic
strength over the range of conditions studied. However, it does predict a minimum binding
capacity occurring at an ionic strength of 0.34 M, which is consistent with the apparent
minimum seen experimentally at 0.30 M. While different salt types clearly contribute to
different protein-ligand adsorption stoichiometries, as indicated in Table 3.2, no correlation
was observed between the salt type (i.e., position in the Hofmeister series) and the number of
hydrophobic ligands (n), the number of exchangeable counter salt ions (v) and the
equilibrium constant (Keq).
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Figure 3. 3 Evaluation of multimodal thermodynamic adsorption model for describing IgG
adsorption isotherms at 22 °C: (a) sodium citrate, (b) sodium chloride, (c) sodium
thiocyanate, Symbols represent experimental data, and curves represent best fits using the
ther modynamic model. (d) Symbols represent experimental data at 75mM NaCl with error
bars from standard deviations among four repeated measurements. Curve shows the isotherm
prediction by the thermodynamic model.
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The model-derived maximum binding capacities, also presented in Table 3.2, are nearly the
same for all three salt types. This result is logical because the multimodal ligands have the
𝑚𝑚𝑚
𝑚𝑚𝑚
same number of hydrophobic and Coulombic functional groups, and, thus, 𝑞𝑝,𝑀𝑀
= 𝑞𝑝,𝐻𝐻𝐻
=

𝑚𝑚𝑚
regardless of the interaction type that predominates. Therefore, unlike the qmax
𝑞𝑝,𝐼𝐼𝐼

parameter in the Langmuir adsorption model, which provides a different apparent binding
capacity at each salt condition (type and ionic strength), the qmax provided by the
thermodynamic model is independent of both the type and concentration of the salt, and
represents the true maximum protein binding capacity of the MMM.

The model parameter Ks is proportional to the difference of intermolecular attractive forces
between protein-water and protein-salt, and Kp is proportional to the difference of
intermolecular attractive forces between protein-water and protein-protein [10]. The results
presented in Table 3.2 clearly show that water-protein interactions are stronger than proteinprotein interactions (Kp > 0) in the presence of NaSCN, indicating that the chaotropic salt
may help to reduce protein aggregates, e.g., in an elution process using this salt. NaCl and
NaSCN are characterized by a predominance of Coulombic interactions, in which Ks < 0,
implying that the salt-protein interactions are stronger than water-protein interactions. In
contrast, sodium citrate promotes hydrophobic interactions and is described by Ks > 0, which
implies stronger water-protein interactions. Our results substantiate the thinking that Ks < 0
describes systems where Coulombic interactions outweigh hydrophobic interactions, with the
reverse true for Ks > 0 [14].
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Table 3. 2 Fitted isotherm parameters for IgG adsorption on the MMM.
Salt

Keq

v

n

NaCitrate
NaCl
NaSCN

131
357
301

1.28
0.24
1.12

0.084
0.007
0.068

Qmax
(mg/mL)
227
217
221

Ks
(M-1)
3.78
-1.30
-1.79

Kp
(mL/mg)
-0.073
-0.284
0.042

Cs,min
(M)
0.34
-

We also used the thermodynamic model to predict an isotherm for a set of non-test
conditions. Fig. 3.2d shows the close correspondence of our predicted isotherm with the
experimental data, clearly indicating the efficacy of the thermodynamic model for describing
the adsorption process through a set of physically meaningful parameters, and for predicting
the adsorption behavior under non-test conditions.

3.4.4 Elution method investigation
The selection of the elution method for multimodal adsorbers is more complicated than the
selection for traditional ion-exchange and hydrophobic interaction chromatography media.
This complexity is due to the occurrence of multiple interaction types between multimodal
functional groups and target molecules, and the strength of these individual interactions,
which varies with changes in the process conditions. Therefore, the interactions of IgG with
the MMM were modulated with different salts and additives to identify an effective elution
strategy for recovering IgG from the MMM adsorbents.
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Figure 3. 4 Influence of different elution modulators on IgG recovery from the MMM: (a)
pH, (b) urea concentration, (c) NaCl concentration, (d) NaSCN concentration.
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Fig. 3.4 (a) shows the effect of solution pH on IgG recovery. The isoelectric point (pI) of IgG
is in the range 6.5−7.5, while the pKa value for the carboxylic acid group on 4mercaptobenzoic acid is 4.80; although, we caution that it is not uncommon for the acidity
constant of a polymeric organic acid to be different from its corresponding monomer value
due to the change of chemical environment in the polymer [20]. For all pH values above 7.5,
the recovery percentages increased with increasing pH. This result is consistent with the fact
that both the MMM and IgG are charged negatively and that the magnitude of the IgG charge
increases with increasing pH above pI. Hydrophobic interactions are independent of the pH,
and contribute to IgG binding capacity at high pH. No significant elution was observed for
pH levels below 5.0. The acid groups of the MMM are protonated at lower pH and allow
hydrogen bonding to occur between the MMM and IgG.

With evidence that the MMM can associate with IgG through hydrogen bonding, urea, a
hydrogen bond disruptor, was expected to affect the strength of IgG interactions with the
MMM. As demonstrated in Fig. 3.4 (b), the percentage recovery increased by increasing the
concentration of urea in the elution buffer.

As described in detail earlier, salt type and concentration affect protein-ligand interactions.
Fig. 3.4 (c) shows the percentage recovery for NaCl used as an elution salt, in which a 23 h
elution yields a percentage recovery that is twice as high as that for a 2 h elution. This result
indicates that NaCl would not be an effective salt for elution, as a slow elution mechanism
would yield a broad peak and, thus, low resolution separations in the dynamic elution
process. From the lowest (0.5M) to highest (1.5M) NaCl concentration, the recovery
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percentage at 23 h increases only ~ 12%. This elution strategy is inefficient; the presence of
hydrophobic interactions can compensate for a partial loss in binding capacity caused by
disruption of Coulombic interactions. In this case, the excellent salt tolerance of the MMM is
a disadvantage.

The use of a chaotropic salt such as NaSCN in an elution method can interrupt both the
Coulombic and hydrophobic interactions. Fig. 3.4 (d) supports this idea, as elution with 0.5
M NaSCN yielded a high recovery percentage (~84%) within 2 h. Increasing the NaSCN
concentration to 1.0 M yielded a 100% recovery percentage after 2 h. This result satisfied our
objective to identify an effective elution strategy for fully recovering IgG from the MMM
adsorbers in a short time. This strategy was used to regenerate MMM columns in the
breakthrough studies described later.

The elution strategies investigated here provide an excellent roadmap for future work using
MMMs for bind-and-elute chromatography. Before MMM chromatography can be of
practical industrial use, comprehensive studies involving other elution modulators and
gradient elution strategies to separate multicomponent mixtures must be undertaken. These
studies are underway in our lab.

3.4.5 Kinetic binding study
A kinetic binding study was conducted to determine the rate of adsorption of IgG on the
MMM discussed in this paper. Fig. 3.5 shows the rate of uptake measured by batch-type
static binding capacity experiments, where each symbol represents the average static binding
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capacity results of two measurements.
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Figure 3. 5 Batch kinetics of IgG binding to the MMM from a solution of 3 mg IgG/ml in 25
mM PBS buffer at pH = 6.5. Contacting was done with agitation at 22 °C. The data represent
average binding capacities from two measurements.

Although the results in Fig. 3.5 indicate an overall high binding capacity, they also show
relatively slow IgG binding kinetics. This may limit the achievable load productivity of the
MMM in a bind-and-elute chromatography process. It has been established that mass
transport of proteins in macroporous membranes modified using the surface-initiated ATRP
technique is governed by convection, rather than diffusion (a major improvement over resin
beds). For purposes of determining if the rate limiting step for the chromatography process is
convective flow or the protein-ligand adsorption reaction, we used Equation 8 to calculate the
78

Damköhler number (Da):
𝐷𝐷 =

𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑟𝑟𝑟𝑟

𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑚𝑚𝑚𝑚 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑟𝑟𝑟𝑟

=

𝑟𝑃𝑃 ×𝑉0

(8)

𝑐𝑝 ×𝑣𝑝

where rPL is the rate of protein adsorption on the MMM, V0 is the MMM bed volume used in
this study; cp is the feed protein concentration; and vp is the flowrate.

The protein-ligand adsorption reaction rate was estimated by linear regression of data in Fig.
3.5 over the first 2 h. The initial slope yields a reaction rate of 0.63 mg/(ml×min). In the
MMM chromatography column, the bed volume is 0.1 mL and a typical feed solution is 3 mg
IgG/mL flowing at a rate of at 0.1 mL/min. The estimated value for Da was therefore 0.2. As
a rule of thumb [21], in this continuous-flow MMM column, Da>10 indicates a sufficiently
rapid protein-ligand reaction rate, in which 90% of the available protein will adsorb onto the
membrane column. However, in our analysis, Da << 10, indicating that the adsorption
reaction in this case was the rate limiting step. It is thought that this slow reaction rate might
possibly originate from the hydrophobicity of the ligands, which affects both the polymer
conformation and the number of easily accessible binding sites. Over time as protein binds
within the polymer layer, it swells and provides access to additional binding sites, resulting in
high equilibrium capacities. However, premature breakthrough will occur if the residence
time is insufficient to allow this process to occur.

3.4.6 Flow rate effect on MMM column back pressure
Fig. 3.6 shows the dependence of the column backpressure on linear flow velocity for MMM
columns. Pressures were recorded after a binding buffer was used to equilibrate the column.
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As expected, we recorded a higher backpressure in the MMM column than in the unmodified
membrane column. This result indicates that the multimodal polymer “tentacles” grafted
from the pore surfaces reduce the pore sizes. The back pressures of the empty column were
measured as a control in this study. At the same linear flow rates, the back pressures for the
empty column were 65-100% of the back pressure for the membrane column, indicating that
the membrane module contributed most of the resistance to flow. For example, at a flow rate
of 531 cm/h (=10 ml/min), backpressures for the MMM column and empty column were
0.49 MPa and 0.32 MPa.
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Empty Column
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2 unmodified membranes
5 unmodified membranes
2 modified membranes
5 modified membranes

Back Pressure, MPa

0.50
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Linear Flowrate, cm/h
Figure 3. 6 Dependence of back pressure on linear flow rate for MMMs (bed height: 140 µm
for 2 membranes and 350 µm for 5 membranes; buffer: 25 mM PBS buffer at pH = 6.5;
module: CIM® BIA Separations, Inc.).

The data show a linear increase in the pressure with an increase in the linear flow velocity, a
relationship anticipated by the Kozeny-Carman equation used to describe the pressure drop
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of a fluid flowing through a packed bed of solids. In addition, the Kozeny-Carman equation
indicates that the pressure drop should increase with an increase in the bed height, which is
supported by the experimental results on membrane columns with different bed thickness.

3.4.7 Dynamic protein binding capacities
To measure the dynamic binding capacities and reusability of the MMM, a bind-and-elute
chromatographic operation was used. Due to the presence of both hydrophobic and
hydrophilic groups, the multimodal polymer chains adjust their geometric orientation
according to buffer flow [10]. Therefore, prior to loading the protein feed, the binding buffer
was pumped through the membrane bed to equilibrate the multimodal polymer chains. After
equilibration, IgG solution was injected into the MMM column, and data collection began at
the time of injection. In our previous study, we found that the optimum pH for IgG
adsorption on the MMM is around 6.5, near its isoelectric point. Therefore, in the dynamic
binding capacity experiments, we fixed the pH at 6.5 for both the binding buffer and the
injected protein solutions.

After the injection, unbound proteins were washed from the membrane bed using a binding
buffer that returned the UV absorbance to the baseline. An isocratic elution strategy was
subsequently used to release the adsorbed protein molecules from the membrane column.
The elution buffer comprised 1M NaSCN in 25 mM PBS buffer. At this condition of high
ionic strength, the Coulombic interactions between the membrane bed and the IgG molecules
were screened by ions in the elution buffer. Furthermore, the presence of NaSCN, a strong
chaotropic salt, also interrupted the hydrophobic interactions between the membrane bed and
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the proteins, as discussed in Section 3.4.2. This elution strategy was effective in fully
regenerating the membrane column; it was reused more than ten times following the same
bind-and-elute protocol, with no subsequent loss in performance.

3.4.7.1 Breakthrough analysis
To determine the dynamic binding capacities of the MMM, a breakthrough analysis was
conducted by monitoring the effluent protein concentration from the AKTA purifier. Fig. 3.7
illustrates the breakthrough curves for unmodified and MMM membrane beds. We measured
the dynamic binding capacities at 10%, 50%, and 95% breakthrough, i.e., where the effluent
concentrations reach 10%, 50% and 95% of the feed concentration. The curve for the
unmodified membrane bed was used to define the dead volume of the system.
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Figure 3. 7 Breakthrough curves for un-modified membrane and MMM (bed height: 420 μm;
bed diameter: 16 mm; feed solution: 3 mg IgG/ml; buffer: 25 mM PBS buffer at pH = 6.5).

Table 3.3 summarizes the DBC results. As expected, the SBC of 127 mg/ml measured in
batch uptake experiments was slightly higher than the 118 mg/ml DBC95%. The capacity at
10% breakthrough, DBC10%, was 56 mg/mL As discussed in Section 4.5, slow binding
kinetics contribute to DBC10% being much lower than SBC. The load productivity at 10%
breakthrough was 10.2 mg/(ml×min), calculated according to the equation developed in prior
research by our group [22]. These results indicate that the new MMM has a sufficiently high
binding capacity for industrial application, with a high productivity relative to commercial
products. There may be room for improvement in load productivity by increasing flow rate;
although, the achievable flow rate will be limited by the protein-ligand reaction rate.
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Table 3. 3 Dynamic binding capacity at difference stages of breakthrough for MMM
prepared using 21 h polymerization time.
Breakthrough Percentage
10%
50%
95%

DBC (mg/ml)
56
80
118

Although it is standard practice to report dynamic capacity at 10% breakthrough, Table 3.3
also presents values for DBC50% and DBC95%. These values may be useful to evaluate the
potential of the MMM for overload and elute purification of antibodies, a technique
described by Nadarajah and Mehta [23].

3.4.7.2 Flow rate effect on dynamic binding capacity
The MMM column was examined under three different flow rates, the dynamic binding
capacity and productivity results of which are presented in Table 3.4. A five-fold increase in
the flow rate decreased DBC10% by only 9%. Despite the minor effect on binding capacity,
this increase in flow rate dramatically increased the load productivity by 4.9 times. Under
these test conditions, the MMM column had a productivity of nearly 11.7 mg/(mL×min),
twice as high as the maximum load productivity for current multimodal resin products (Table
3.1). Increasing process productivity is beneficial to the quality of the protein products, as
long purification time is detrimental to both the stability and activity of proteins [24,25].

3.4.7.3 Ionic strength effect on dynamic binding capacity
Table 4 also summarizes the effect of ionic strength on protein dynamic binding capacity of
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the MMM column. Compared to the dynamic binding capacity of 47 mg IgG/ml at 0 mM
NaCl in 25 mM PBS buffer, the MMM bed retained 81% and 70% of the binding capacity at
150 mM and 300 mM NaCl in 25 mM PBS buffer. Results from dynamic capacity
measurements validate our previous claim based on equilibrium measurements that the
MMM has excellent salt tolerance [10]. The ability of the MMM to bind protein under
conditions of high ionic strength may eliminate the need for feedstock conditioning (e.g.,
desalting or dilution) to optimize loading following a Protein A capture step. Decreasing the
number of steps would be particularly useful for improving the downstream purification
process of therapeutic proteins, which are sensitive to processing times.

The MMM prepared in this study is being evaluated as a less expensive alternative to Protein
A chromatography. Protein A resins cost almost an order of magnitude more than nonaffinity media [26]. Thus, processes that replace Protein A chromatography with ion
exchange and hydrophobic interaction chromatography [27,28] could reduce purification
costs significantly. Studies along these lines with our MMM are under way and will be
published in the future.

Table 3. 4 The effect of flow rate and sodium chloride concentration on MMM IgG dynamic
binding capacity at 10% breakthrough and load productivity.
Flowrate (CV/min)

NaCl (mM)

DBC (mg/mL)

1
1
1
3
5

0
150
300
0
0

47
38
32.4
45
43
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Productivity
(mg/mL/min)
2.4
3.0
3.0
7.2
11.7

3.5 Conclusions
Our newly designed multimodal membrane (MMM) is characterized by high protein binding
capacities and high load productivity. IgG equilibrium binding capacity was insensitive to
sodium citrate concentration over the range of concentrations used in elution buffers of
Protein A columns, which indicates that the elution pool from Protein A chromatography
could be loaded directly on the MMM without desalting.

A thermodynamic model was used to provide insights on the nature of protein-MMM
interactions and to predict binding capacities under non-test conditions, which is important
for limiting the number of experiments needed for process development.

It also was determined that the rate limiting step of IgG adsorption on the MMM is the
reaction rate of IgG binding with the multimodal ligands, rather than the mass transport of
protein molecules. Thus, while high load productivities were achieved, improvements in
membrane design leading to faster adsorption kinetics would enable still higher
productivities.

Taken together, the results of this study strengthen the argument that multimodal membrane
bind-and-elute chromatography can be a highly productive and scalable process. The ability
to work at high salt concentrations may reduce the number of steps in the protein purification
train, improving product quality, enhancing manufacturing capacity in existing facilities, and
reducing the cost of downstream purification. To facilitate membrane chromatography
process development, research is needed to develop a model framework to predict
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breakthrough curves on MMM column. Investigations also are needed to test the newly
designed membranes for recovery of proteins from complex bioprocess streams. These
studies are under way in our lab and will be published in the future.
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Chapter Four

ANTIBODY PURIFICATION FROM CHO CELL SUPERNATANT USING NEW
MULTIMODAL MEMBRANES

4.1 Introduction
Monoclonal antibodies (mAbs) are in high demand to treat chronic conditions such as cancer,
cardiovascular disease, and autoimmune disorders, et al. The US FDA has approved more
than 30 mAbs and another >300 mAbs are currently under clinical development [1,2]. It is
estimated that the sales of approved mAbs will reach $125 billion in 2020 [2]. These drugs
are expensive and difficult to produce. The average monthly cost for branded drug treatment
is about $10,000 [3]. The high cost is associated in part with the complex manufacturing
process, which generally has more than 30 unit operations [4], including multiple
chromatography operations.

Shukla and Thömmes [5] describe the downstream process platform for mAb production,
which starts with a chromatographic capture step and includes two subsequent polishing
chromatographic steps for impurity removal. Most manufacturers have adopted Protein A
chromatography as the platform capture step for commercial scale mAb production [6].
Protein A has a high specificity to the Fc region of antibodies [7,8], which allows process
impurities such as host cell proteins (HCPs), DNA, and virus particles to flow through while
the product binds. However, Protein A chromatography has disadvantages and limitations.
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Firstly, mAb purification by Protein A chromatography is strongly case dependent. Ghose et
al. [9] showed that the same Protein A column may have a range of dynamic binding
capacities (DBCs) for different mAbs. The low pH of elution buffers used in Protein A
chromatography may cause mAb unfolding and generate protein aggregates and isoforms,
requiring further purification to satisfy regulatory requirements [10]. In some cases, Protein
A chromatography fails because the mAbs cannot be stabilized at low pH.

Secondly, the combination of low, flow rate-dependent DBCs; long residence time; and high
resin cost complicates Protein A chromatography scale up for mAb manufacturing, especially
considering that the mAb titer in the fermentation step has increased in some cases to >10
g/L in recent years. Most Protein A resins have DBCs lower than 40 mg/mL [11], although
GE now offers a product with DBC slightly higher than 60 mg/mL at long (6 min) residence
time [12]. The price of Protein A resins is substantially higher than that of ion-exchange
resins, and ranges from $9,000 to $12,000/L for reusable products. Thus, a Protein A resin
column with a diameter of 1 m and a typical bed height of 50 cm costs several million US
dollars. Hence, biomanufacturers tend to use smaller columns for multicycle purifications,
leading to a long purification time and a low throughput process [13].

Thirdly, due to degradation by proteases in the feedstock and conditions applied in clean-inplace operations, Protein A ligands leach from the resin surface. Although Protein A columns
maintain performance after 50 cycles [12,14], leached Protein A is a toxic process-related
impurity that may cause immunogenic reactions in patients and trigger the formation of
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aggregates in process, and increases the clearance burden of subsequent chromatography
steps [15,16].

Following Protein A chromatography in the mAb purification platform are one or more ionexchange chromatography steps and, in some cases, hydrophobic interaction
chromatography. These polishing steps are used to reduce residual process and productrelated impurities, including HCPs, DNA, endotoxins, leached Protein A, and high molecular
weight product aggregates, to acceptable levels. These steps also contribute to validation of
virus clearance. Conventional ion-exchange materials used for polishing require
preconditioning of feed pH and conductivity and offer low selectivity. Multimodal or mixed
mode materials are less sensitive to conductivity and pH and offer higher selectivity [17].

Commercial mixed mode resins such as Pall MEP HyperCelTM and GE CaptoTM MMC have
been studied frequently [16,18-21]. Gantier and coworkers [16] used high throughput
screening and design of experiments to compare anion exchange mixed-mode resin
chromatography and Protein A chromatography. They suggested that mixed mode resins are
especially efficient at decreasing aggregate levels to low levels (<0.5%) while attaining mAb
yields >90% and HCP levels <2500 ppm after one step purification.

While Protein A chromatography is used widely, there are examples of non-affinity
chromatographic methods for protein capture. Synagis and Humira are commercial mAbs
that are purified using cation-exchange (CEX) chromatography as the capture step [22], and
there are at least another 29 submissions in CDER regulatory documents that indicate the use
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of a non-Protein A capture step [18]. Appealing features of CEX capture include comparable
purity and yield to Protein A chromatography [22], lower materials cost than Protein A
media, and dynamic binding capacities of 100 mg/mL or higher. CEX capture avoids
concerns over leached Protein A and also can avoid low pH elution conditions. Further, nonaffinity methods will be used more regularly as the industry develops biologics without Fc
binding domains and encounters proteins intolerant of low pH.

To overcome the need for preconditioning of feed conductivity in the use of CEX
chromatography, we previously reported the development of a multimodal CEX membrane
adsorber (hereafter referred to as MMM) with high dynamic binding capacity, high load
productivity, and excellent salt tolerance using synthetic feed solutions [23,24]. The objective
of the current study was to demonstrate the feasibility of using MMM for capture step
purification from real clarified Chinese hamster ovary (CHO) cell culture supernatant. To
improve the direct capture efficiency by the MMM, a desalting column was used to remove
chaotropic salts from the cell supernatant. The MMM was operated in bind-and-elute mode
using a neutral pH elution buffer. A comparison was made between the desalting-MMM
chromatography process and Protein A chromatography. The mAb purity and HCP level in
the elution pool were assessed and compared for both purification methods. Both methods
were challenged with typical process conditions.
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4.2 Materials and Methods
4.2.1 Cell culture supernatant
CHO cells (ATCC® CRL-12445) were grown in CD CHO medium (Life Technologies, NY,
USA) supplemented with 5 mM glutamine with anti-clumping agent (1:250) (Life
Technologies) to express the human monoclonal antibody (IgG1) against Interluekin-8 (IL8). Cells were seeded at approximately 2 × 105 cells/mL in 75 cm2 flasks (Corning Inc, NY,
USA) incubated at 37°C in humidified 5% CO2 and shaken at 120 rpm. The hIgG1 was
harvested when the cell concentration reached approximately 2 × 106 cells/mL. The cells
were removed by centrifugation at 1000 g and the clarified CHO cell culture supernatant was
stored at –20°C. Prior to chromatography operations, aliquots were thawed and filtered
through disposable cellulose acetate syringe filters (0.2 μm, VWR). The culture supernatant
contained 100 mg/L hIgG1 and the HCP content was 6,700 ppm.

4.2.2 Chemicals and buffers
Chemicals and sources were bromophenol blue (1610404, Bio-Rad), citric acid (≥99.5%,
Sigma-Aldrich), ethylenediaminetetraacetic acid (EDTA, ≥99%, Sigma-Aldrich), glycerol
(≥99%, Sigma), glycine (≥99%, Sigma), hydrochloric acid (HCl (aq), 37%, Sigma-Aldrich),
Immunoglobulin G from bovine serum (IgG, 95% mixture of IgG1, IgG2, IgG3, IgG4, MP
Biomedicals, LLC), phosphate buffered saline (PBS, 1X, Fisher Bioreagents), pmercaptoethanol (99%, Amresco), sodium chloride (NaCl, ≥99%, Sigma-Aldrich), sodium
dodecyl sulfate (SDS, 470302, Ward’s Science), sodium hydroxide (97%, Alfa Aesar),
sodium thiocyanate (NaSCN, ≥98%, Sigma-Aldrich), and Tris base (≥99.8%, J.T. Baker).
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Buffer B1 (20 mM PBS buffer, adjusted to pH = 6.45 by HCl) was used for protein binding
capacity measurements. Buffer B2 was prepared by adding 0.15 M NaCl to Buffer B1 and
used for equilibrating the desalting column. Buffer E1 (0.1 M citric acid with pH = 3.0) was
used to elute protein from the Protein A column. Buffer E2 (1.0 M NaSCN with pH 8.0) was
used to elute protein from the MMM column. All buffers were prepared with Milli-Q®
Ultrapure (EMD-Millipore, Bedford, MA) water and then sonicated prior to use.

4.2.3 Assay materials
Assay materials and sources were precast polyacrylamide gels (4-20% gradient, 10-well,
Bio-Rad), bovine γ-globulin protein assay kit (Bio-Rad Protein Assay Kit I 5000001),
Precision Plus ProteinTM All Blue Standards (Bio-Rad 1610374), Bio-safe Coomassie Stain
solution (Bio-Radn 1610787), Pierce silver stain kit (ThermoFisher Scientific 24612), and
Anti-CHO HCP detection kit (Pall ForteBio LLC 18-5081).

4.2.4 Chromatographic methods
The MMMs were developed and prepared in our laboratory, as described previously [25,26].
The membranes comprise a macroporous regenerated cellulose membrane with a coating of
poly(glycidyl methacrylate) that is modified by reaction with 4-mercaptobenzoic acid. The
MMMs were cut into 18 mm diameter discs and stacked into a Mustang® Coin membrane
module purchased from Pall Corporation (Port Washington, NY). Multiple membranes were
stacked to produce a 0.1 mL adsorptive bed volume. Prior to loading membranes into the
module, membranes were soaked in methanol and loading Buffer B1.
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HiTrap Protein A HP resin column (1 mL bed volume, 0.7 cm diameter and 2.5 cm length)
and HiPrep 26/10 Desalting resin column (15 mL bed volume, 2.6 cm diameter and 10 cm
length) were purchased from GE Healthcare Bio-Sciences.

An ÄKTA Purifier 100 (GE Healthcare Bio-Sciences, Uppsala, Sweden) was used for all
protein chromatography measurements. IgG protein solution or CHO cell supernatant was
loaded onto columns from a 50 mL capacity SuperloopTM (GE Healthcare Bio-Sciences). The
effluent from the chromatography column was monitored continuously with UV detection at
280 nm and pH and conductivity detectors. All data were recorded and viewed in Unicorn
5.31 software (GE Healthcare Bio-Sciences).

Commercial IgG was used as a model protein to measure protein dynamic binding capacities
of MMM and Protein A stationary phases. IgG solutions were prepared with a concentration
of 3 mg/mL in loading Buffer B1. Prior to use, the protein solution was filtered through a 0.2
μm disposable cellulose acetate syringe filter.

Protein dynamic binding capacity and equilibrium binding capacity were determined by an
overload and elute chromatography method. The same equilibration and protein loading steps
were used for both Protein A and MMM columns. Firstly, the columns were equilibrated
with 15 column volumes (CVs) of loading Buffer B1. Next, IgG was loaded onto the column
by passing 3 mg/mL IgG solution through the column at a flow rate of 1 CV/min until the
protein concentration in the effluent reached its feed concentration. Lastly, the bound protein
was eluted from the column until a stable baseline was observed with UV detection at 280
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nm. Elution Buffer E1 was used to recover IgG from the Protein A column, and elution
Buffer E2 was used for the MMM column. Dynamic binding capacity was calculated at 10%
breakthrough according to Equation 1:
𝑞=

𝐶0 (𝑉𝑏𝑏𝑏𝑏𝑏 −𝑉𝑑𝑑𝑑𝑑 )
𝑉𝑐𝑐𝑐

(1)

q represents the binding capacity, mg/mL; Vbreak represents the effluent volume where the
UV absorbance value reached 10% of the value of the feed solution, mL; Vdead is the dead
volume of the system, mL; C0 is the protein feed concentration, mL; and Vcol is the stationary
phase column volume, mL. Equilibrium (static) binding capacities (mg/mL) were determined
by Equation 2:
𝑞𝑒 =

𝑀𝑝

𝑉𝑐𝑐𝑐

(2)

qe represents the equilibrium binding capacity, mg/mL; Mp is the protein mass in mg
calculated from the protein elution peak area. A calibration curve was developed relating the
mass of protein to the 280 nm peak area of a protein standard.

A two-step chromatography sequence was used to capture and purify hIgG1 from CHO cell
supernatant. In the first step, a HiPrep 26/10 column was used to remove chaotropic salts.
The desalting column was connected to the ÄKTA purifier system and equilibrated with
loading Buffer B2 until a stable base line was observed with UV-detection at 280 nm. Next, 5
mL CHO cell supernatant was loaded onto the column at 15 mL/min, followed by Buffer B2.
The first peak from the column contained the product hIgG1. It was collected for loading onto
the MMM column. In the second step, the MMM column was connected to the ÄKTA
Purifier system and equilibrated by flowing loading Buffer B1 at 1 mL/min through the
column until a stable base line was observed with UV detection at 280 nm. The hIgG1
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solution collected from the desalting column was loaded onto the MMM column at 0.1
mL/min (residence time of 1 min), followed by washing of unbounded protein with 10 mL
loading Buffer B1. The bound proteins were eluted using a step elution with Buffer E2. The
elution peak was collected for SDS-PAGE analysis.

To compare the separation performance, Protein A chromatography also was evaluated for
direct capture of hIgG1 from the CHO cell supernatant. The Protein A column was installed
in the ÄKTA purifier system and equilibrated with loading Buffer B1. Next, 20 mL CHO cell
supernatant was loaded onto the column at 1 mL/min (residence time of 1 min). Ten
milliliters of loading Buffer B1 was passed through the column to wash out unbound proteins.
Bound proteins were eluted using step elution with Buffer E1. The elution peak was collected
for SDS-PAGE analysis.

4.2.5 Sample analysis
The feed cell supernatant and elution fractions from Protein A column, desalting column and
MMM column were analyzed by SDS-PAGE. Total protein content in each fraction and feed
CHO cell supernatant were determined using a bovine γ-globulin protein assay kit with 75
μL of sample mixed with 25 μL of loading buffer. To prepare a local calibration curve for
densiometric analysis of each gel, IgG standard samples were loaded onto every SDS-PAGE
gel. One-dimensional SDS-PAGE was performed using precast 4-20% gradient gels and 500
mL running buffer (1X Tris-HEPES-SDS) in a Mini-Protein Tetra Cell (Bio-Rad
Laboratories, Inc.) according to the experimental procedure provided by the manufacturer.
All gels were run at a constant 200V. Gels were stained using a silver stain kit.
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The detection of residual host cell protein contaminants was conducted by using a Pall
ForteBio-Cygnus Anti-CHO HCP detection kit. The feedstock CHO cell supernatant and
hIgG1 elution pools collected from Protein A chromatography and MMM chromatography
were analyzed according to the experimental procedures provided by the manufacturer. To
quantify the HCP level in the samples, a set of HCP standards (5, 10, 15, 20 μg/mL) was
prepared by using 20 μg/mL CHO Antigen. A buffer-only control was used as a reference.

4.3 Results and discussion
We previously designed and produced the first weak cation multimodal membrane using
surface-initiated ATRP [25]. These macroporous MMMs were shown to have high IgG
binding capacities that were insensitive to solution ionic strength, particularly for citrate salt.
For this reason, the MMMs are highly effective for polishing step purification (without buffer
exchange/dilution) following a Protein A chromatography step, which commonly uses citrate
buffer for product elution.

In this study, our primary objective was to evaluate the capture step purification of hIgG1
using the weak cation MMM column and compare its performance with a commercial
Protein A resin column. The capture step purification was evaluated on material from actual
cell culture supernatant. Bind-and-elute chromatography was used to purify hIgG1 from CHO
cell culture supernatant using either MMM or Protein A stationary phase. A secondary
objective of this study was to compare IgG dynamic binding capacity of the MMM and
Protein A resin columns at an equivalent residence time of 1 min. A synthetic protein
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solution was used to compare dynamic binding capacities of the two columns.

4.3.1 Monoclonal antibody binding capacity
Protein binding capacities of MMM and Protein A resin columns were determined from
bind-and-elute chromatography operations. Bovine IgG was used as the model protein to test
the stationary phase binding capacities. The dynamic binding capacities were determined
from breakthrough curve measurements under the same loading conditions. The volumetric
flow rate was 1 CV/min (1 min residence time). The equilibrium binding capacities were
determined by the mass of protein in the elution peaks following column overloading.

Figures 4.1 and 4.2 shows bind and elute chromatograms for MMM and Protein A resin
columns. The bovine IgG solution was injected until the protein concentration in the effluent
reached its feed concentration as indicated by an absorbance of about 680 mAu. The bound
protein was eluted with appropriate elution buffers until a stable UV absorbance baseline was
observed. Although the bovine IgG was recovered fully from both columns, the elution pool
from the Protein A column was enriched in bovine IgG (6 mg/mL) compared to the feed (3
mg/mL); whereas, the elution pool from the MMM column was diluted (1.2 mg/mL). Current
work is exploring alternative elution strategies to improve the peak resolution, which is
needed to overcome product dilution, as we have shown for other membrane chromatography
processes [27].
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Figure 4. 1 Overload and elute curve for MMM column (loading Buffer B1: 20 mM PBS,
pH=6.45; elution Buffer E2: 1 M NaSCN; sample loading flow rate: 0.1 mL/min; sample
load volume: 30 mL; bed volume: 0.1 mL). The feed solution was 3 mg IgG/mL in Buffer
B1. Solid line represents the absorbance at 280 nm. Long dash line represents conductivity.
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Figure 4. 2 Overload and elute curve for Protein A resin column (loading Buffer B1: 20 mM
PBS, pH=6.45; elution Buffer E1: 0.1M citric acid, pH=3.0; sample loading flow rate: 1
mL/min; sample load volume: 30 mL; bed volume: 1 mL). The feed solution was 3 mg
IgG/mL in Buffer B1. Solid line represents the absorbance at 280 nm. Long dashed line
represents pH of the effluent.

Table 4. 1 Bovine IgG binding capacity of MMM column and Protein A resin column.
Stationary phase

MMM
Protein A resin

Dynamic binding capacity
(mg/mL) at 10%
breakthrough
47±4
13.3±2

Equilibrium binding capacity
(mg/mL)
118±5
18±3

Table 4.1 summarizes the equilibrium binding capacities of MMM and Protein A columns.
Compared with the Protein A resin column, the new MMM column has 4 times higher
bovine IgG dynamic binding capacity at an equivalent residence time of 1 min, and 6 times
higher protein equilibrium binding capacity. The HiTrap Protein A column has a degree of
substitution of 3 mg Protein A ligand/mL. If one assumes a 2:1 binding of IgG to Protein A,
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this column could bind up to 22 mg IgG/mL, consistent with the equilibrium binding
capacity that we measured. The higher binding capacity of the MMM is attributed to the
high grafting density and degree of polymerization of polymer chains grafted from the
membrane pore surfaces.

4.3.2 Monoclonal antibody purification with two different chromatography strategies
Working with model protein solutions such as bovine IgG allows for the proof of concept
development of a new material; however, to have practical significance the material must
also perform when challenged with actual process material. Working with actual process
solutions also allows for troubleshooting problems that would not be encountered working on
model protein solutions. Thus, the next step was to challenge the MMM with hIgG1 from cell
culture supernatant. Protein A resin and MMM were used as stationary phases to purify the
hIgG1 protein from CHO cell supernatant using an overload and elute strategy. Volumetric
flow rates were selected to achieve a common residence time of 1 min. The optimum pH for
bovine IgG binding on the MMM was pH 6.45 [25], and a pH of 6-7 is recommended for
Protein A chromatography [28]. Therefore, pH=6.45 was selected to prepare binding buffers
for both stationary phases.
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Figure 4. 3 Protein A chromatography used to capture human IgG1 from CHO cell
supernatant (loading Buffer B1: 20 mM PBS, pH=6.45; elution Buffer E1: 0.1 M citric acid,
pH=3.0; sample loading flow rate: 1 mL/min; sample load volume: 20 mL; bed volume:
1mL). Solid line represents the absorbance at 280 nm. Long dashed line represents pH of the
effluent.

Figure 4.3 presents the chromatogram for hIgG1 purification from CHO cell supernatant
using the Protein A resin column. The sample was loaded onto the column until the protein
concentration in the effluent reached its feed concentration as indicated by an absorbance of
about 840 mAu. The hIgG1 antibody binds selectively to Protein A ligands, while HCPs and
other process contaminants flow through; although a low occurrence of non-specific
interactions may lead to some bound impurities. The bound hIgG1 was eluted with an
appropriate elution buffer producing a sharp peak. This fraction was collected and pooled for
SDS-PAGE analysis.
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Figure 4. 4 Desalting column used to remove chaotropic salts from CHO cell supernatant
(running buffer-loading Buffer B2: 150 mM NaCl in 20 mM PBS, pH=6.45; sample loading
flow rate: 15 mL/min; sample load volume: 5 mL; bed volume: 53 mL). The effluent volume
between the two vertical dotted lines was collected as the hIgG1-rich fraction.
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Figure 4. 5 MMM chromatography used to capture hIgG1 from the protein-rich fraction
collected from the desalting column effluent (loading Buffer B1: 20 mM PBS, pH=6.45;
elution Buffer E2: 1.0 M NaSCN, pH=8.0; sample loading flow rate: 0.1 mL/min; sample
load volume: 2 mL; bed volume: 0.1 mL). Solid line represents the absorbance at 280 nm.
Long dashed line represents conductivity of the effluent.

Figures 4.4 and 4.5 show results of the purification strategy to capture hIgG1 from CHO cell
supernatant using a size-exclusion desalting column followed by MMM chromatography.
The desalting operation was used to remove chaotropic salts reported in the cell culture
medium[29], since our previous study [24] has shown that chaotropes interrupt protein
binding to the MMM. From a protein sample load volume study with the desalting column, it
was found that a 5 mL sample CHO cell supernatant volume gave sufficiently high peak
resolution. Therefore, 5 mL of cell culture supernatant was loaded onto the desalting column.
Running Buffer B2 was pumped through the desalting column and proteins and salts eluted
based on hydrodynamic size. To prevent accumulation of material in the column, 150 mM
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NaCl was added into the running Buffer B2 to suppress Coulombic interactions with the
desalting column. The fraction from 15 to 23 mL (9 mL total) in Figure 4 was collected as
the hIgG1 product fraction for SDS-PAGE analysis and subsequent loading on the MMM
column. Peaks eluted from the desalting column after the product peak correspond to lower
molecular weight proteins, peptides and other UV absorbing compounds in the cell medium.

The MMM column was equilibrated with binding Buffer B1. A 2 mL portion of the hIgG1
fraction collected from the desalting column was loaded on the column. The reported
isoelectric point of hIgG1 is 8.6±0.4 [30]. Therefore, at pH 6.45, positively charged hIgG1
molecules bind to the negatively charged MMMs. At the same time, hydrophobic domains on
the protein molecules also interact with hydrophobic groups on the MMMs, which helps to
maintain the high binding capacity even under conditions of 150 mM NaCl used in the
desalting column. In Figure 4.5, data collection was started when the hIgG1 solution was
injected. As the protein fraction is loaded on the MMM column, contaminants and proteins
not conditioned to bind on the column pass through the column and appear as the first peak
in Figure 4.5. Bound proteins were eluted with a step elution using Buffer E2 (1M NaSCN in
Buffer B1, pH=8.0). As we described previously [26], the chaotropic salt NaSCN interrupts
both the Coulombic interactions and hydrophobic interactions between the adsorbed proteins
and the MMM. Increasing the pH to 7.5 shifts the net charge of the hIgG1 which helps to
release the bound protein from the MMM column. The second peak in Figure 4.5 is the
elution peak that was collected for analysis.
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SDS-PAGE analysis was conducted to evaluate the performance of the MMM and Protein A
resin to separate and purify the hIgG1 from the CHO cell supernatant. The peak collected
from the Protein A column was 2 mL and had a total protein concentration of 1.1 mg/mL.
The peak collected from the MMM column was 2 mL and had a total protein concentration
of 0.053 mg/mL.

Figure 4. 6 Comparison of Protein A and MMM columns for the purity of hIgG1 from CHO
cell supernatant. Lane 1, molecular weight markers; Lane 2, unpurified CHO cell supernatant;
Lane 3, elution pool collected from Protein A column; Lane 4, protein-rich fraction collected
from desalting column; Lane 5, elution pool collected from MMM column.

SDS-PAGE gels were stained using silver stain solution to visualize the hIgG1 and other
proteins within the elution peaks collected from the Protein A and MMM columns (Figure
4.6). For comparison, SDS-PAGE gels stained using Coomassie blue stain are included in the
Supplementary Materials. Silver staining allows for visualization of extremely low levels of
protein in a sample (0.25 ng/lane), where Coomassie blue has a typical detection limit of
around 7 ng/lane). The CHO cell supernatant major protein was the hIgG1, as indicated in
Figure 4.6, Lane 2 by the distinctly dark bands at 50 and 25 kDa, corresponding to the heavy
and light chains of the hIgG1. However, there were also significant amounts of CHO cell109

derived proteins, as the media used to culture the cells contained no proteins and was
chemically defined. As expected, the Protein A column resulted in high purity hIgG1, as
shown in Figure 6, Lane 3. Additionally, the two-step MMM process resulted in a high purity
hIgG1, as shown in Figure 4.6, Lane 5. Quantitative evaluation by UV-vis densiometric
analysis of the gels confirmed this result, which is significant because it suggests that MMM
chromatography following a simple desalting step could be an excellent option for capture
step purification of proteins when Protein A chromatography is not an option.

Table 4. 2 Performance comparison of MMM and Protein A chromatography columns used
for capture step purification of hIgG1.
Column
Protein A

MMM

Feed

Load

Cell
20 Column
Supernatant Volumes
Protein
Rich
Fraction

20 Column
Volumes

Elution
Condition
0.1 M
citrate
pH=3.0
1.0 M
NaSCN
pH=8.0

Recovery

Purity

HCP
(ppm)

97±2%

>98%

20

100±2%

>98%

n.d.

Table 4.2 compares the Protein A and two-step MMM purification methods based on hIgG1
purity, recovery, and HCP level. Both methods achieved a very high recovery rate, although
both require some compromise. The MMM method requires a desalting step to achieve high
recovery; whereas, Protein A chromatography requires acidic elution conditions that may
inactivate protein products and increase the level of aggregates.

In the manufacturing of biopharmaceuticals, residual HCPs from CHO cells carry substantial
risk of decreasing efficacy of the drug and causing adverse immunogenic reactions in
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patients. Therefore, the detection of residual HCP contaminates has become a critical step for
drug safety and qualification. As a rule, HCPs should not exceed 100 ppm [31]. In this study,
ForteBio quantification analysis with an anti-CHO HCP detection kit was used to detect the
level of HCP in hIgG1 product fractions. Table 4.2 shows that the HCP levels in the Protein
A and MMM product fractions were very low compared to the HCP level in the feedstock,
which was about 6,700 ppm. This result indicates that both methods have high selectivity for
separating hIgG1 from CHO cell supernatant. Since the separation mechanism of MMM
chromatography is based on Coulombic and hydrophobic interactions and does not require
the product to have an Fc binding domain, the proposed two-step MMM chromatography
process could be used to selectively capture and purify most target proteins.

4.4 Conclusions
Overall, this study demonstrated that MMM chromatography can be a high-capacity, high
selectivity separation technique for protein capture. When used after a size exclusion
desalting step, the MMM column was effective for recovery of hIgG1 from CHO cell culture
supernatant, and neutral pH elution yielded a product pool with purity (>98%) and HCP level
(n.d.) equivalent to what could be achieved by Protein A chromatography. Dynamic
capacities at 1 CV/min were higher for the MMM column than the commercial Protein A
resin column, which is important for reducing the number of cycles needed for purification of
a batch and thereby increasing process throughput.

Whereas it is unlikely that Protein A chromatography will be replaced anytime soon for mAb
capture step purification, MMM chromatography following a simple desalting step appears to
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be an excellent option for capture step purification of proteins when Protein A cannot be
used, e.g., for pH sensitive mAbs or biologics lacking the Fc binding domain.
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CHAPTER 5
CONCLUSIONS AND RECOMMENDATIONS

5.1 Conclusions
The overall goal of my PhD research was to design the first weak cation multimodal
membrane material for downstream purification of therapeutic proteins. The concept of this
work was to develop a multimodal membrane incorporating ligands that can bind proteins
through a combination of Coulombic interactions and hydrophobic interactions. I realized
this goal and showed that this advancement could widen the operation ranges for
chromatographic separations. I showed that the membrane bears the merits of high binding
capacity, high productivity and high selectivity. I demonstrated that using the membrane
material addresses some of the pain points related to purification process capacity and cost
experienced by the biopharmaceutical industry.

In the first part of the project, I developed a two-step surface-modification method to prepare
the weak cation multimodal membranes for chromatographic bioseparations. Macroporous
support membranes were modified by grafting poly(glycidyl methacrylate) (PGMA)
‘tentacles’ and subsequent reaction with 4-mercaptobenzoic acid. PGMA chains on the
membrane provide an ideal platform to incorporate multimodal ligands, and serve as a
scaffold for achieving a high density of protein binding sites on the membranes. This
platform can form the basis for future adsorptive membrane designs. I performed a kinetic
study to understand the relationship between polymer chain length and protein binding
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capacity. A cellulose coated silicon wafer was used to mimic the membrane surface. The
study suggested that the degree of polymerization is an important contributing factor to the
protein binding on the membrane. This study system can be used as the basis for future
adsorptive membrane designs. Protein binding experiments with bovine immunoglobulin G
showed that static binding capacities of the multimodal membranes were dependent on pH
and ionic strength. I demonstrated that the multimodal membranes are extraordinarily salt
tolerant: within a wide sodium citrate concentration range (from 0 M to 1 M), the equilibrium
IgG binding capacity decreases by only ~10% from the lowest to highest ionic strength
conditions. This ability to maintain capacity in citrate buffer means that the MMM could be
used directly following a Protein A capture step without a desalting operation. No other
commercial membrane available today can make that claim.

In the second part of the project, I demonstrated the advantages of this multimodal membrane
compared with commercial multimodal resin products. Firstly, the dynamic binding capacity
of the macroporous MMMs was insensitive to the throughput. High loading productivity was
achieved by simply increasing the flow rate. In addition, the transmembrane pressure
remained below 2 bar up to a relatively high flow rate 10 ml/min (535 cm/h, 100 column
volume/min). Another advantage of this MMM adsorber is its ultra-high binding capacity
(maximum equilibrium binding capacity >180 mg IgG/mL and dynamic binding
capacity >56 mg IgG/mL). Taken together, the MMM is able to process a large volume of
feed solution in a short residence time at low transmembrane pressure.

I developed an improved thermodynamic model to further understand the protein adsorption
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behavior on the multimodal membranes. The model provides a unique set of physically
meaningful parameters to describe the protein adsorption. I introduced Langmuir model
parameters for initial linear slope estimation to overcome the inherent limitations of the
thermodymic model. I also used the model to understand the effects of salt type (kosmotropic
salts and chaotropic salts) and ionic strength on the protein adsorption; to determine the true
maximum binding capacity (~ 220 mg IgG/mL); and to evaluate the relative strengths among
solvent-protein, protein-salt, and protein-protein interactions. I successfully demonstrated
that this model can provide a good description of experimental data and be used to predict
multimodal membrane binding capacities under non-test conditions.

Subsequently, I conducted a systematic study to investigate the salt effects on protein binding
capacity. Kosmotropic salts enhance hydrophobic interactions, which compensates for the
loss of Coulombic interactions as ionic strength increases. Thus within a wide range of ionic
strengths studied, the kosmotropic salt had a minor effect on the MMM IgG binding capacity.
Dynamic testing confirmed that the membranes maintain high capacity during flow. Overall,
development of a membrane which can achieve such high capacities at high ionic strength is
a major breakthrough, since traditional ion-exchangers would have zero binding at these salt
conditions. On the other side of the Hofmeister series, chaotropic salts interrupt both
Coulombic and hydrophobic interactions, and were found to be effective at releasing IgG
from the multimodal membrane.

In the third part of the project, I used MMM chromatography as primary capture step to bind
human IgG1 from CHO cell culture supernatant and compared its performance with Protein
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A chromatography. The MMM demonstrated a high selectivity for capturing human IgG1
from CHO cell culture supernatant following a desalting step to remove chaotropic salts.
Following column loading, a chaotropic salt was used to elute the product at neutral pH to
prevent aggregates formation in the MMM chromatography. A high quality protein product
was obtained from the MMM chromatography purification step. The proposed two-step
desalting-MMM chromatography operation has merit for capture step purification of proteins,
especially in cases where Protein A chromatography can not be applied (e.g., pH sensitive
protein products or those without an Fc binding domain).

In summary, using the MMM material is appealing for several reasons: 1) Dynamic protein
binding capacities of the material generally do not depend on throughput. Therefore,
volumetric productivity can be very high compared to more traditional chromatography
materials. This will help to alleviate the tradeoff that manufacturers must now take between
processing time and dynamic binding capacity. 2) The multimodal membrane could replace
the traditional cation exchangers used after the Protein A chromatography step without
requiring a desalting operation. It can reduce buffer usage and the number of operations in
the downstream purification processes. 3) When used in a two-step desalting-MMM
chromatography process, it provides an alternative to Protein A for the primary capture step.
For reasons indicated above, utilization of the MMM in place of a resin column operation
would offer the advantages of improving overall product quality, yield and purification time.

5.2 Recommendations
While the project has contributed new ideas for solving emerging challenges in industry,
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some work remains to be done to fill in remaining technology gaps.

Firstly, I would suggest developing new polymerization strategies to graft polymer chains
from the substrate membrane. In this study, I grafted reactive polymer tentacles first, and
then introduced the functional ligands onto the membrane. The advantage of this approach is
that a simple wash step following ligand incorporation is all that is needed. However,
reaction conditions must be controlled so that the epoxide side groups react with ligand
molecules without forming excessive cross-links. A highly cross linked polymer can affect
the accessability of binding sites when biomolecules approach the membrane. One idea
would be to form the functional monomer first, and then grow polymer chains from the
membrane substrate. In this case, the challenge would be separation and purification steps in
the organic synthesis to achieve a high purity monomer. Of course, this method could
eliminate the formation of cross links.

My second suggestion also relates to the design of polymer chains. In my study, I noticed
that the hydrophobicity/hydrophilicity balance of the membrane materials is very important
for application to protein purifications. Since feed streams to the downstream
chromatography operations are aqueous solutions, the polymer chains should be hydrophilic
and therefore highly extended to facilitate protein uptake. However, to prepare a multimodal
membrane material that combines both ionic and hydrophic groups, the membrane may
become hydrophobic after coating with multimodal polymer chains. If they are too
hydrophobic, then they will collapse onto the membrane surface and limit protein
accessibility. As observed in my study, the high hydrophobicity of the materials leads to the
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slow protein uptake kinetics and, therefore, a large difference between equilibrium binding
capacity and dynamic binding capacity at 10% breakthrough. Ellipsometric swelling
measurements could provide insights on how to balance hydrophilicity/hydrophobicity to
maintain high equilibrium binding capacity while keeping the layer well hydrated and
accessible to proteins. Hydrophilic monomers such as oligoethylene glycol methacrylate or
hydoxyethyl methacrylate could be introduced into the polymer chain to adjust this balance.

Thirdly, while not a focus of this study, I developed a new method to coat cellulose
nanolayers on silicon wafers to mimic the surface morphology of cellulose membrane
materials. Such surfaces can be used for the ellipsometry measurements just described.
However, one of the challenges was that the nanolayers had large values of root mean square
roughness after spin coating. Rectangular wafers were used in this study because they were
available; however, they introduce edge effects during the spin coating. Using circular wafers
may yield smoother coated surfaces, or perhaps blade coating could achieve smoother
cellulose nanolayers on the silicon wafers.

Fourthly, for the multimodal membrane chromatography, it is a very promising unit
operation can be used as following Protein A step and primary step in a standard mAb
downstream purification process. To purify protein products, chromatography adsorbers
should be very selective and the elution method should be effective. In this project, I have
demonstrated that the MMM material has a very high selectivity to capture monoclonal
antibodies from CHO cell culture supernatant. More work need to be done in the
development effective elution methods. I have started this study by using arginine, NaCl and
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pH. An additional paper will be finished by the end of my PhD program.

Finally, regarding the separation performance evaluation, I would strongly suggest a
comprehensive study on the module design. Firstly, the module material has to be compatible
with the protein solutions and be stable under cleaning conditions using strong base/acid
solutions. Secondly, the inlet should achieve a good distribution of the feed flow onto the
wide surface of the membrane column. The outlet should be designed with a low dead
volume to avoid mixing. Thirdly, the module design should accommodate a larger volume of
membrane bed. A spiral wound configuration would facilitate scale up.

122

APPENDICES

123

Appendix A
Figure 1.1 Reproduced Permission

ELSEVIER LICENSE
TERMS AND CONDITIONS
Jun 20, 2016
This Agreement between Juan Wang ("You") and Elsevier ("Elsevier") consists of your
license details and the terms and conditions provided by Elsevier and Copyright Clearance
Center.
License Number 3893070918809
License date Jun 20, 2016
Licensed Content Publisher Elsevier
Licensed Content Publication Trends in Biotechnology
Licensed Content Title Recent advances in large-scale production of monoclonal antibodies
and related proteins
Licensed Content Author Abhinav A. Shukla,Jörg Thömmes
Licensed Content Date May 2010
Licensed Content Volume
Number
28
Licensed Content Issue
Number
5
Licensed Content Pages 9
Start Page 253
End Page 261
Type of Use reuse in a thesis/dissertation
Portion figures/tables/illustrations
Number of figures/tables
/illustrations
1
Format both print and electronic
Are you the author of this
Elsevier article?
No
Will you be translating? No
Order reference number
Original figure numbers figure 3
Title of your
thesis/dissertation
Development of a New Multimodal Membrane Adsorber and Its
Application in Chromatographic Bioseparations
124

Expected completion date Aug 2016
Estimated size (number of
pages)
150
Elsevier VAT number GB 494 6272 12
Requestor Location Juan Wang
807 College Ave. Apt.17
CLEMSON, SC 29631
United States
Attn: Juan Wang
Total 0.00 USD

125

Appendix B
Elution Method Development for MMM Chromatography
1. Introduction
Protein aggregation has become a great challenge for manufacturing of biopharmaceuticals.
Compared with monomeric proteins, the biological activity of the aggregates is very different
and can significantly impair the potency of a protein-based drug. Many environmental factors
can lead to aggregation, which includes temperature, pH, ionic strength, shear force, oxygen
and protein concentrations [1]. Numerous strategies are used to reduce the level of aggregates
in protein products, which includes protein engineering, expression system selection,
separation in downstream purification process and storage formulation buffer screening.
Separation in downstream purification process is of particular interest because it makes the
biggest contribution on aggregates removal. It typically involves multiple chromatography
steps, in which difference separation principles are used such as affinity, charge, size,
hydrophobicity etc.

In a standard mAb downstream purification platform, Protein A chromatography is typically
used as the first step to isolate proteins from cell culture supernatant. This step is not able to
remove aggregates because product aggregates may bind to the ligands through affinity
interactions as well as monomeric product. Besides, since mAb are eluted at low pH in this
Protein A chromatography step and a virus inactivation step follows at low pH, more
aggregates may be formed during these operations. It has been reported that [2] in the
preparation of CamPath-1H, the elutes from Protein A column contained approximately 25%
aggregated mAb.
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Ionic exchanger chromatography has been reported to be useful at production scale to
separate mAb monomers from oligomers [3], as aggregates may carry more charge than
overall net charge of the monomer product. It is also feasible to separate mAb from
aggregates using hydrophobic chromatography. Because hydrophobicity of mAb increases
with aggregation [4].

Multimodal chromatography, whose adsorbers bind target molecules through multiple
interactions, is the promising operation for improving the downstream process because of its
improved selectivity and the ability to reduce the number of operations. It also been widely
used in antibody purifications for decades. Pizarro and his coworkers [5] have reported using
Capto MMC to capture recombinant human vascular endothelial growth factors (rhVEGF)
expressed in E. coli. The refolding pool, which contained urea, provided a challenging
feedstock for the rhVEGF capture at pH9.8. Because of the significant amount of rhVEGF
that precipitated in CEX or AEX columns, the low ionic strength of the pool did not support
an HIC-based capture. Therefore, MMC is a powerful tool for challenging feedstocks. In
Chen et al. [6] study, both MEP, a hydrophobic charge induction resin, and Ceramic
hydroxyapatite/fluoroapatite (CHT/CFT) resins could considerably reduce the amount of
impurities and the formation of insoluble aggregates. Husson and his coworks have also
developed the first weak-cation multimodal membrane (MMM) chromatography [7,8], which
with the merits of high binding capacity, great salt tolerace, high productivity and high
selectivity.
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However, the elution conditions for multimodal chromatography are complex, as multiple
interactions take place simultaneously. For example, concentrated salt buffer could interrupt
coulombic interactions between proteins and multimodal adsorbers, but may also enhance
other interactions like hydrophobic interaction at the same time [9,10]. Conversely, organic
solvents interrupt hydrophobic interaction while enhancing coulombic interactions[11-13].
Arginine can be used as elution agent for the complex situation with multimodal
chromatography. It has been demonstrated that arginine is very effective on suppressing
protein aggregation and precipitation, and it is also widely used for protein formulation,
protein refolding and protein solubilization [14,15].

In this study, we examined the effects of arginine on the elution of monoclonal antibody from
the new multimodal membrane adsorbers [7] in comparison to NaCl elution. Arginine is
found to be very effective on protein elution and aggregates removal.

2. Materials and Experiments
2.1 Cell culture supernatant
CHO cells (ATCC® CRL-12445) were grown in CD CHO medium (Life Technologies, NY,
USA) supplemented with 5 mM glutamine with anti-clumping agent (1:250) (Life
Technologies) to express the human monoclonal antibody (IgG1) against Interluekin-8 (IL8). Cells were seeded at approximately 2 × 105 cells/mL in 75 cm2 flasks (Corning Inc, NY,
USA) incubated at 37°C in humidified 5% CO2 and shaken at 120 rpm. The hIgG1 was
harvested when the cell concentration reached approximately 2 × 106 cells/mL. The cells
were removed by centrifugation at 1000 g and the clarified CHO cell culture supernatant was
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stored at –20°C. Prior to chromatography operations, aliquots were thawed and filtered
through disposable cellulose acetate syringe filters (0.2 μm, VWR). The culture supernatant
contained 100 mg/L hIgG1 and the HCP content was 6,700 ppm.

2.2 Chemicals and buffers
Regenerated cellulose membranes (RC 60) with 1.0 µm average effective pore diameter and
70 µm thickness were purchased from Whatman, Inc. L-arginine (≥98%, Sigma-Aldrich),
citric acid (≥99.5%, Sigma-Aldrich), hydrochloric acid (HCl (aq), 37%, Sigma-Aldrich),
Immunoglobulin G from bovine serum (IgG, 95% mixture of IgG1, IgG2, IgG3, IgG4, MP
Biomedicals, LLC), phosphate buffered saline (PBS, 1X, Fisher Bioreagents), sodium
chloride (NaCl, ≥99%, Sigma-Aldrich), sodium thiocyanate (NaSCN, ≥98%, SigmaAldrich), and Tris base (≥99.8%, J.T. Baker).

Buffer B (25 mM PBS buffer, adjusted to pH=6.45 by HCl). Buffer E1 (1 M arginine in
buffer B with pH=9.0). Buffer E2 (1 M NaCl in buffer B with pH=9.0). Buffer E3 (0.5 M
arginine in buffer E2 with pH=9.0). All buffers were prepared with Milli-Q® Ultrapure
(EMD-Millipore, Bedford, MA) water and then sonicated prior to use.

2.3 Screening on elution conditions
The multimodal membrane adsorbers used in this study were prepared by a surface
modification of regenerated cellulose membranes. A two-step membrane modification
process was used as described in our previously publication [7].
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The screening experiments were conducted in batch bases. Bovine Immunoglobulin G (IgG)
was used as a model protein to measure protein adsorption/elution behavior of the MMMs.
IgG concentration of 3.0mg/mL (c0) was prepared in buffer B. In a typical elution study
experiment, a MMM (cut into 18mm diameter) was placed in 20 mL glass vials and
incubated in 2 mL of IgG solution for 20 h to reach binding equilibrium in a shaker bath at
22 °C, 70 rpm. After 20 h, membranes were removed from the protein solutions and then put
into another 20 mL glass vials with an elution buffer of 2 mL. The membrane was incubated
in the elution buffer for 2 h in a shaker bath at at 22 °C, 70 rpm. Finally, equilibrium
concentration of protein solutions (ce) and equilibrium concentrations of elution buffers (cb)
were measured by UV-vis and UV absorbances at 280 nm were recorded. Recovery rate were
calculated by mass balance using initial and equilibrium concentrations, as described in
equation (1).
𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 =

𝑐𝑒
× 100%
𝑐0 − 𝑐𝑏

(1)

Two full factorial design of experiments were conducted in this elution study to investigate
arginine and sodium chloride effects on protein elution from the MMM. The key factors of
the DoEs are salt concentrations and pH, and key response is recovery. The following table
lists all the studied elution conditions.
Table 1 Screening elution conditions on MMM using design of experiments
Factors

Levels

Salt type

NaCl or Arginine

Salt concentration (M)

0.1, 0.5, 1.0

pH

5.0, 7.0, 9.0
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Responses

Recovery (maximize)

2.4 Chromatographic methods
The membranes were subsequently placed into a Mustang Coin module with a stack volume
of 0.1 mL. Bovine IgG was firstly used to evaluate the elution strategies with the MMM
chromatography. IgG was dissolved into binding buffer B to prepare a 3.0 mg/mL solution.
The protein solution was placed into a shaker bath at 22 °C to dissolve, and the solution was
subsequently filtered through disposable cellulose acetate syringe filters with 0.2 µm pore
diameter to remove any protein aggregates. To induce soluble irreversible aggregates, the
IgG solution was heated at 60 °C for 18 h.

A human monoclonal (mAb) antibody (IgG1) against interleukin-8 (IL8) was furtherly used
to examine the promising elution strategies with MMM chromatography. Cell supernatant
culture with the human IgG1-IL8 was firstly centrifuged and filtered through disposable
cellulose acetate syringe filters with 0.2 µm pore diameter (Puradisc 30, GE Healthcare BioSciences) to remove any cell debris and protein aggregates. Then the cell supernatant culture
was loaded on to a Protein A column to isolate the mAb from other contaminates. 1M of
sodium citric solution at pH=3 was used to elute proteins from the Protein A column. The
effluent was collected and held in the low pH solutions for 24 h to induce aggregates.

The MMM chromatography was performed in a bind-and-elute mode. The MMM column
was firstly equilibrated with 10 mL binding buffer B followed by protein sample injection,
washout unbounds proteins and elution. Detailed chromatographic conditions are provided in
section 3. After each run, the column was regenerated with 1M NaSCN followed by binding
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buffer B equilibration. Protein recovery was estimated by measuring the absorbance at 280
nm multipled by the elution volume. Aggregates level was measured by HPLC (described in
section 2.5).

2.5 HPLC analysis
The levels of IgG aggregation were measured by analytical size exclusion HPLC. The
column was an AdvanceBio SEC 300 Å (Agilent, PL1580-3301) with analytical guard
column (Agilent, PL1580-1301). The mobile phase was 150 mM PBS buffer at pH 7.2. The
flow rate was 0.35 mL/min, ran for 80 min per injection. The IgG was detected by UV
absorbance ar 280 nm, and peaks were integrated manually.

3. Results and discussion
3.1 Screening of elution conditions on MMM
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Figure 1 IgG recovery at different elution conditions.
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1.0

This MMM has a ligand with multimodal functionality, which means that different types of
interactions, such as Coulombic interactions, hydrophobic interactions and hydrogen binding
may occur when proteins bind with ligands. Even though the multimodal ligands enable
binding of proteins at high salt concentrations, it does limit elution using only increasing salt
concentration. In this study, the recovery of IgG in an elution buffer (2 mL, at different pH,
salt type and concentration) was measured to investigate elution conditions for MMM. Figure
1 shows that both pH and salt concentration have effects on elution of bound proteins.
Additionally, the type of salt also affects elution.

When IgG solution (in 25 mM PBS buffer at pH=6.5) was applied to MMM, IgG bound to
the MMM. At low pH (pH=5), the bound IgG could not be significantly eluted using 1M
NaCl (10%~ 20%), which is typically used in eluting proteins from ionic exchange
chromatography (IEC) by reducing Coulombic interactions. One the other side, significant
amount of IgG (up to 60%) were eluted using 1 M arginine at pH=5, suggesting that arginine
has a stronger ability to interrupt interactions. As increasing the pH up to 9, the overall net
charge of IgG becomes into negative, and therefore, strong charge repulsion should happen
between negatively charged IgG and MMM. However, IgGs were only partially recovered
from MMM in NaCl elution buffers. The persistent binding of IgG can be explained in two
possibilities: first, the loss of coulombic interaction can be partially compensated by
promoted hydrophobic interaction; second, local positive charges on IgG play a key role on
protein binding with the negatively charged MMM. In the case of arginine, bound IgG can be
effectively eluted from the MMM column at pH=9. As increasing the concentration of
arginine in elution buffer, the recovery of IgG is also increased and 1M arginine is sufficient
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to elute nearly all of the bound IgG. This suggests that arginine weakened not only
coulombic interactions (as is the case for NaCl) but also interrupted hydrophobic interactions
due to the special properties of arginine. Furthermore, the high recovery of IgG with using
arginine also indicates that the observed persistent binding in the case of NaCl at pH 9.0 is
the result of promoted hydrophobic interaction as aforementioned first possibility, since NaCl
increase the hydrophobic interactions while simultaneously reduce coulombic interactions.
Both rising pH and increasing salt concentrations are needed to maximize recovery of IgG
from the MMM. Elution with arginine generally gives a higher recovery than elution with
NaCl. This is due to the guanidinium group in arginine lead to a strong electronic screening
effect [16], and additionally, arginine could also interrupt hydrophobic interactions between
proteins and aromatic groups on the MMM.

3.2 Elution bovine IgG from the MMM column
Due to the stronger interaction with proteins compared with conventional single mode
chromatography (such as IEX, HIC), MMM not only demonstrates different protein elution
profile, but also offers the possibility to separate protein oligomers from monomers. Firstly,
when the working pH is approaching to the protein products pI, the overall net charge of the
protein is close to zero. Aggregates generally carry more charge than the product within this
pH range. If the sample is applied to an IEX column, most of the aggregates tend to bound on
to the column. Secondly, aggregations of mAbs are more hydrophobic than its monomers.
Thus, it is practical to separate mAb from aggregates based on differences of hydrophobicity.
In this study, both NaCl and arginine were used to investigate the ability of MMM on
separating proteins oligomers.
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Figure 2 Chromatograms of gradient elution of bovine IgG from MMM column using 1 M
NaCl in 25 mM PBS buffer at pH=9.0 (loading buffer: 25 mM PBS buffer at pH=6.5, flow
rate: 0.5 mL/min, sample load: 6 mL 3mg/mL bovine IgG). Solid line represents the
absorbance at 280 nm. Dotted line represents conductivity. Dashed line represents the % of
elution buffer.

From the results of Dynamic Light Scattering (DLS), no aggregation is formed due to
increase protein concentration within the protein concentration range from 0 to 10 mg IgG/
mL. To induce soluble irreversible aggregation, feed solution was prepared by heating 3
mg/mL IgG at 60 °C for 16 h. After the heat treatment, the feed solution contains about 10
~13% aggregates. The MMM chromatography was operated in a bind and elute mode. Figure
2 shows the elution profile of heat treated IgG from MMM chromatography using NaCl as
elution agent. The peak shown around 7 mL correspond to the flow-through (FT) and it
contained about 5.8% aggregates. The reduction of aggregates level in FT sample indicates
aggregates tend to bound on the membrane column. This is due to the increased charge and
hydrophobicity of aggregation. The broad peak at about 24 mL is from NaCl gradient elution.
The collection from this peak contained about 10% aggregates with a low recovery of 16.5%.
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In figure 3, gradient elution using arginine produced a sharper elution profile in compared
with gradient elution with NaCl. This agrees with the stronger elution capability of arginine.
The first elution peak corresponding to the peak at 18.5 mL contained about 7.5%
aggregates, and the peak at 21 mL contained about 9.7 % aggregates. The results support
arginine gradient elution is able to reduce the aggregates level in protein products while
achieving a high recovery ( ~70%). However, since the protein sample is bovine IgG
solution- a mixture of IgG1, IgG2, IgG3, IgG4, the arginine gradient elution might also cause
the separation of different IgG subclasses.

Figure 3 also shows elution peaks are at earlier low salt fractions, which indicates that a low
concentration of arginine is sufficient to remove most of bound proteins from MMM column.
Taking economic factor into consideration, we investigated the elution profile using both
NaCl and arginine as elution agents in MMM chromatography. A set of 1M NaCl elution
buffers were added with 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 M arginine, and all of the
pHs were adjusted to 9.0. IgG can be fully recovered with 0.5~1.0M arginine and 1M NaCl
elution buffers. Therefore, the elution buffer used in this study was 0.5 M arginine and 1M
NaCl in 25 mM PBS buffer with pH 9.0. A linear gradient elution resulted in the elution peak
shown around 19 mL in Figure 4. The collection from this peak contained 8% aggregates.
The elution collection from 21 mL to 23 mL contained 13% aggregates. Overall, the peak
resolution can be significantly improved by adding arginine in NaCl elution buffer, but IgG
recovery of the elution peak was not high (~ 40%) due to the extensive tailing of this
gradient elution.
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Figure 3 Chromatograms of gradient elution of bovine IgG from MMM column using 1 M
Arginine in 25 mM PBS buffer at pH=9.0 (loading buffer: 25 mM PBS buffer at pH=6.5,
flow rate: 0.5 mL/min, sample load: 6 mL 3mg/mL bovine IgG). Solid line represents the
absorbance at 280 nm. Dotted line represents conductivity. Dashed line represents the % of
elution buffer.
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Figure 4 Chromatograms of gradient elution of bovine IgG from MMM column using 0.5 M
arginine and 1 M NaCl in 25 mM PBS buffer at pH=9.0 (loading buffer: 25 mM PBS buffer
at pH=6.5, flow rate: 0.5 mL/min, sample load: 6 mL 3mg/mL bovine IgG). Solid line
represents the absorbance at 280 nm. Dotted line represents conductivity. Dashed line
represents the % of elution buffer.
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3.3 Elution of human IgG1 against interleukin-8 from MMM column
We furtherly study the effects of arginine on protein elution using human IgG1-Il8. After
condition the MMM column with binding buffer (25 mM PBS at pH 6.5), the hIgG1-IL8
sample was directly loaded on the MMM column. Positively charged hIgG-IL8 should bind
with negatively charged MMM through Coulombic interaction. However, the protein sample
was the effluent from Protein A and at a pH of 3, which results in partially protonating the
MMM. Therefore, in figure 5, a small elution peak around 14 mL was observed
corresponding the low binding capacity. With analysis of elution pool (the effluent collected
between the dash line), arginine was still very effective on protein recovery, but there is no
aggregation resolution as we expected.
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Figure 5 Chromatograms of gradient elution of hIgG1-IL8 from MMM column using 1 M
arginine in 25 mM PBS buffer at pH=9.0 (loading buffer: 25 mM PBS buffer at pH=6.5, flow
rate: 0.5 mL/min, sample load volume: 2 mL). Solid line represents the absorbance at 280
nm. Dotted line represents conductivity. Dashed line represents the % of elution buffer.
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4. Conclusion
In this study, screening of elution conditions on MMM chromatography was studied using
design of experiments. From the batch uptake experiments, both arginine and NaCl were
used to study protein elution from MMM chromatography. Overall, arginine was more
effective than NaCl on the recovery of IgG. In addition, an increase in pH and salt
concentration also promotes the elution of proteins from MMM column. To furtherly
understand the capability of MMM on separating protein aggregation, bind-and-elute
chromatography were conducted at high pH elution condition with different elution salts.
Due to the distinctive properties, arginine can be used to effectively elute IgG from MMM
column with high recovery and good aggregation resolution. The major advancement of this
study is that MMM chromatography can be used as following protein A step without
desalting operation and be very promising on removing aggregates by using arginine as
elution agent. This contribution can greatly reduce the number of operations in downstream
purification process of therapeutic protein production.
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